Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],2.75,1270,DB00193,Tramadol
,19710642,area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)),The median area under plasma concentration-time curve extrapolated to infinity (AUC(0-infinity)) of (+)-M1 was 2.75 micromol/l.h after placebo pretreatment compared with 1.95 micromol/l.h after escitalopram (P = 0.0027).,Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),[μM] / [h·l],1.95,1271,DB00193,Tramadol
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,140",1272,DB00193,Tramadol
,19710642,AUEC(1-12),"The mean AUEC(1-12) of CPT were 4,140 and 4,388 cm.s after placebo and escitalopram, respectively (P = 0.71).",Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19710642/),cm·s,"4,388",1273,DB00193,Tramadol
,11499486,recoveries,"The method developed was selective and linear for concentrations ranging from 50 to 3,500 ng/ml (tramadol) and 50 to 500 ng/ml (M1) with mean recoveries of 94.36 +/- 12.53% and 93.52 +/- 7.88%, respectively.",Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499486/),%,94.36,2618,DB00193,Tramadol
,11499486,recoveries,"The method developed was selective and linear for concentrations ranging from 50 to 3,500 ng/ml (tramadol) and 50 to 500 ng/ml (M1) with mean recoveries of 94.36 +/- 12.53% and 93.52 +/- 7.88%, respectively.",Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499486/),%,93.52,2619,DB00193,Tramadol
,11499486,Limit of quantitation (LOQ),Limit of quantitation (LOQ) was 50 ng/ml.,Validation of a high-performance liquid chromatography method for tramadol and o-desmethyltramadol in human plasma using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499486/),[ng] / [ml],50,2620,DB00193,Tramadol
,23802666,half-lives,"At steady state following 4.5 days of twice-daily administration, the mean half-lives for plasma tramadol and M1 concentrations were 2.92 ± 0.78 hours and 2.14 ± 0.07 hours, respectively.",Pharmacokinetics of repeated oral administration of tramadol hydrochloride in Hispaniolan Amazon parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802666/),h,2.92,3317,DB00193,Tramadol
,23802666,half-lives,"At steady state following 4.5 days of twice-daily administration, the mean half-lives for plasma tramadol and M1 concentrations were 2.92 ± 0.78 hours and 2.14 ± 0.07 hours, respectively.",Pharmacokinetics of repeated oral administration of tramadol hydrochloride in Hispaniolan Amazon parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802666/),h,2.14,3318,DB00193,Tramadol
,19189983,rate,"The rate constants associated with the metabolite elimination [0.144 h(-1), (+)-M1 and 0.18 h(-1), (-)-M1] were smaller than the elimination rate constants of the parent drugs [0.243 h(-1), (+)-tramadol and 0.241 h(-1), (-)-tramadol], suggesting that the metabolite disposition was rate-limited by its elimination.",Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189983/),1/[h],0.144,11299,DB00193,Tramadol
,19189983,rate,"The rate constants associated with the metabolite elimination [0.144 h(-1), (+)-M1 and 0.18 h(-1), (-)-M1] were smaller than the elimination rate constants of the parent drugs [0.243 h(-1), (+)-tramadol and 0.241 h(-1), (-)-tramadol], suggesting that the metabolite disposition was rate-limited by its elimination.",Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189983/),1/[h],0.18,11300,DB00193,Tramadol
,19189983,elimination rate constants,"The rate constants associated with the metabolite elimination [0.144 h(-1), (+)-M1 and 0.18 h(-1), (-)-M1] were smaller than the elimination rate constants of the parent drugs [0.243 h(-1), (+)-tramadol and 0.241 h(-1), (-)-tramadol], suggesting that the metabolite disposition was rate-limited by its elimination.",Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189983/),1/[h],0.243,11301,DB00193,Tramadol
,19189983,elimination rate constants,"The rate constants associated with the metabolite elimination [0.144 h(-1), (+)-M1 and 0.18 h(-1), (-)-M1] were smaller than the elimination rate constants of the parent drugs [0.243 h(-1), (+)-tramadol and 0.241 h(-1), (-)-tramadol], suggesting that the metabolite disposition was rate-limited by its elimination.",Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19189983/),1/[h],0.241,11302,DB00193,Tramadol
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.33,12391,DB00193,Tramadol
,29092654,metabolic ratios,"3. The metabolic ratios of O-desmethyltramadol, the product of CYP2D-mediated metabolism of tramadol, in normal and diabetic control rats were found to be 0.33 ± 0.12 and 0.29 ± 0.07, respectively.","Changes in CYP2D enzyme activity following induction of type 2 diabetes, and administration of cinnamon and metformin: an experimental animal study. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29092654/),,0.29,12392,DB00193,Tramadol
,11999728,lambda(ex,"Fluorescence detection (lambda(ex) 202 nm/lambda(em) 296 nm for tramadol and its metabolite, lambda(ex) 264 nm/lambda(em) 344 nm for N1,N1-dimethylsulfanilamide) was used.",High-performance liquid chromatographic determination of tramadol and its O-desmethylated metabolite in blood plasma. Application to a bioequivalence study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999728/),nm,202,13963,DB00193,Tramadol
,11999728,lambda(ex,"Fluorescence detection (lambda(ex) 202 nm/lambda(em) 296 nm for tramadol and its metabolite, lambda(ex) 264 nm/lambda(em) 344 nm for N1,N1-dimethylsulfanilamide) was used.",High-performance liquid chromatographic determination of tramadol and its O-desmethylated metabolite in blood plasma. Application to a bioequivalence study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999728/),nm,264,13964,DB00193,Tramadol
,17532170,flow rate,"Chromatographic separation was achieved with a Chromolith Performance RP-18e 100 mm x 4.6 mm column, using a mixture of methanol:water (19:81, v/v) adjusted to pH 2.5 by phosphoric acid, in an isocratic mode at flow rate of 2 ml/min.","Improved liquid chromatographic method for the simultaneous determination of tramadol and its three main metabolites in human plasma, urine and saliva. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532170/),[ml] / [min],2,14816,DB00193,Tramadol
,26309104,terminal half-life,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,1.56,15188,DB00193,Tramadol
,26309104,maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],155.6,15189,DB00193,Tramadol
,26309104,time to maximum serum concentration,"The terminal half-life, maximum serum concentration, and time to maximum serum concentration for tramadol following naïve pooled modeling were 1.56 hours, 155.6 ng/mL, and 3.90 hours, respectively.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.90,15190,DB00193,Tramadol
,26309104,maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),[ng] / [ml],7.90,15191,DB00193,Tramadol
,26309104,time to maximum serum concentration,"For hydrocodone, maximum serum concentration determined by naïve pooled modeling was 7.90 ng/mL, and time to maximum serum concentration was 3.47 hours.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,3.47,15192,DB00193,Tramadol
,26309104,terminal half-life,"The terminal half-life for hydrocodone was 15.85 hours, but was likely influenced by delayed drug absorption in some dogs and may not have been a robust estimate.",Pharmacokinetics of hydrocodone and tramadol administered for control of postoperative pain in dogs following tibial plateau leveling osteotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26309104/),h,15.85,15193,DB00193,Tramadol
,28603935,bioavailability,Oral tramadol bioavailability was low (2.6%).,The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,2.6,15349,DB00193,Tramadol
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,18.2,15350,DB00193,Tramadol
,28603935,bioavailability,"Ketoconazole and cimetidine significantly increased tramadol bioavailability to 18.2% and 20.3%, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),%,20.3,15351,DB00193,Tramadol
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[ng] / [ml],22.9,15352,DB00193,Tramadol
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],109.9,15353,DB00193,Tramadol
,28603935,maximum plasma concentration,"The mean maximum plasma concentration of tramadol alone was 22.9 ng/ml, and increased to 109.9 and 143.2 μg/ml with ketoconazole and cimetidine, respectively.",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],143.2,15354,DB00193,Tramadol
,28603935,minimum concentration,"However, measured tramadol plasma concentrations were below the minimum concentration considered effective in humans (228 μg/ml).",The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28603935/),[μg] / [ml],228,15355,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],1316.87,16103,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],1418.02,16104,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],1838.29,16105,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],342.56,16106,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],475.4,16107,DB00193,Tramadol
,27140798,AUC,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[h·ng] / [ml],636.13,16108,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],203.75,16109,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],165.35,16110,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],226.92,16111,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],34.93,16112,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],38.42,16113,DB00193,Tramadol
,27140798,Cmax,"Area under the curve of tramadol and its metabolite M1 in children and adolescents was lower compared with adults (Dose-normalized [DN] AUC, h ng/mL: tramadol: 1316.87 [children]; 1418.02 [adolescents];1838.29 [adults]; M1: 342.56 [children]; 475.4 [adolescents]; 636.13 [adults]) while the Cmax remained similar (DN Cmax , ng/mL: tramadol: 203.75 [children]; 165.35 [adolescents]; 226.92 [adults]; M1: 34.93 [children]; 38.42 [adolescents]; 52.14 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ng] / [ml],52.14,16114,DB00193,Tramadol
,27140798,CL/F,"The weight normalized oral clearance of tramadol was higher in children and adolescents compared with adults (CL/F, mL/min/kg: 12.66 [children]; 11.75 [adolescents]; 9.06 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ml] / [kg·min],12.66,16115,DB00193,Tramadol
,27140798,CL/F,"The weight normalized oral clearance of tramadol was higher in children and adolescents compared with adults (CL/F, mL/min/kg: 12.66 [children]; 11.75 [adolescents]; 9.06 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ml] / [kg·min],11.75,16116,DB00193,Tramadol
,27140798,CL/F,"The weight normalized oral clearance of tramadol was higher in children and adolescents compared with adults (CL/F, mL/min/kg: 12.66 [children]; 11.75 [adolescents]; 9.06 [adults]).",Single- and multiple-dose pharmacokinetic studies of tramadol immediate-release tablets in children and adolescents. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27140798/),[ml] / [kg·min],9.06,16117,DB00193,Tramadol
,18557166,bioavailability,"Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).",Pharmacokinetics of oral tramadol in patients with liver cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),%,98,22264,DB00193,Tramadol
,18557166,bioavailability,"Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).",Pharmacokinetics of oral tramadol in patients with liver cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),%,75,22265,DB00193,Tramadol
,18557166,bioavailability,"Tramadol bioavailability showed a substantial increase in patients with primary liver cancer and secondary metastatic than that of control (98 percent, 75 percent, and 68 percent, respectively).",Pharmacokinetics of oral tramadol in patients with liver cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),%,68,22266,DB00193,Tramadol
,18557166,area under the serum concentration-time curve,"The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].",Pharmacokinetics of oral tramadol in patients with liver cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),[μg] / [h·l],"1,933",22267,DB00193,Tramadol
,18557166,area under the serum concentration-time curve,"The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].",Pharmacokinetics of oral tramadol in patients with liver cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),[μg] / [h·l],"1,327",22268,DB00193,Tramadol
,18557166,area under the serum concentration-time curve,"The area under the serum concentration-time curve increased significantly in patients with primary and metastatic cancer of liver than in control [1,933 microg/h/L (SD = 41), 1,327 microg/h/L (SD = 51), 1,138.5 microg/h/L (SD = 31), respectively].",Pharmacokinetics of oral tramadol in patients with liver cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557166/),[μg] / [h·l],"1,138.5",22269,DB00193,Tramadol
,18313955,C(max) (maximum plasma concentration,"The median values of C(max) (maximum plasma concentration), T(max) (time to maximum plasma concentration) and T(1/2) (half-life) for tramadol were 0.04 (0.17-0.02)mirog mL(-1), 3 (4-2) and 1.88 (2.211-1.435)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),[mirog] / [ml],0.04,23750,DB00193,Tramadol
,18313955,T(max) (time to maximum plasma concentration),"The median values of C(max) (maximum plasma concentration), T(max) (time to maximum plasma concentration) and T(1/2) (half-life) for tramadol were 0.04 (0.17-0.02)mirog mL(-1), 3 (4-2) and 1.88 (2.211-1.435)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,3,23751,DB00193,Tramadol
,18313955,T(1/2) (half-life),"The median values of C(max) (maximum plasma concentration), T(max) (time to maximum plasma concentration) and T(1/2) (half-life) for tramadol were 0.04 (0.17-0.02)mirog mL(-1), 3 (4-2) and 1.88 (2.211-1.435)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,1.88,23752,DB00193,Tramadol
,18313955,C(max),"M5 showed median values of C(max), T(max) and T(1/2) of 0.1 (0.19-0.09)microg mL(-1), 2 (3-1) and 4.230 (6.583-1.847)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),[μg] / [ml],0.1,23753,DB00193,Tramadol
,18313955,T(max),"M5 showed median values of C(max), T(max) and T(1/2) of 0.1 (0.19-0.09)microg mL(-1), 2 (3-1) and 4.230 (6.583-1.847)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,2,23754,DB00193,Tramadol
,18313955,T(1/2),"M5 showed median values of C(max), T(max) and T(1/2) of 0.1 (0.19-0.09)microg mL(-1), 2 (3-1) and 4.230 (6.583-1.847)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,4.230,23755,DB00193,Tramadol
,18313955,C(max),"M2 showed median values of C(max), T(max) and T(1/2) of 0.22 (0.330-0.080)microg mL(-1), 4 (7-3) and 4.487 (6.395-1.563)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),[μg] / [ml],0.22,23756,DB00193,Tramadol
,18313955,T(max),"M2 showed median values of C(max), T(max) and T(1/2) of 0.22 (0.330-0.080)microg mL(-1), 4 (7-3) and 4.487 (6.395-1.563)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,4,23757,DB00193,Tramadol
,18313955,T(1/2),"M2 showed median values of C(max), T(max) and T(1/2) of 0.22 (0.330-0.080)microg mL(-1), 4 (7-3) and 4.487 (6.395-1.563)h, respectively.",Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: a pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18313955/),h,4.487,23758,DB00193,Tramadol
,24806910,Tmax,M1 was quantified over a shorter time period (0.083-6 h) with a Tmax at 0.821 h.,Pharmacokinetics of tramadol and its major metabolite after intramuscular administration in piglets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24806910/),h,0.821,24139,DB00193,Tramadol
,24806910,minimum effective concentration,The human minimum effective concentration of M1 (40 ng/mL) was exceeded for over 3 h in piglets.,Pharmacokinetics of tramadol and its major metabolite after intramuscular administration in piglets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24806910/),[ng] / [ml],40,24140,DB00193,Tramadol
,22595262,flow rate,"The separation was performed on LichroCART RP-18e with particle size of 5 µm (250 × 4.6 mm) with mobile phase acetonitrile-50 mM KH(2)PO(4) buffer, pH 7.1, using a gradient mode with a 1.0 mL/min flow rate.",New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),[ml] / [min],1.0,24703,DB00193,Tramadol
,22595262,Recovery,Recovery values for the substances ranged between 59 and 83%.,New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),%,59 and 83,24704,DB00193,Tramadol
,26508138,V/F,"The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50% longer mean elimination half-life in the elderly.",Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26508138/),l,305,25619,DB00193,Tramadol
,26508138,V/F,"The population analysis identified age as a covariate of V/F (young 305 L; elderly 426 L), with a 50% longer mean elimination half-life in the elderly.",Pharmacokinetics of Tramadol and O-Desmethyltramadol Enantiomers Following Administration of Extended-Release Tablets to Elderly and Young Subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26508138/),l,426,25620,DB00193,Tramadol
,31161580,maximum possible treatment-related effect,"However, the Emax parameter was 2.5 times higher in the elderly and maximum possible treatment-related effect was 169 (135-221) in the young and 194 (149-252) in the elderly; that is, 15% higher in the elderly.",Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31161580/),,169,27699,DB00193,Tramadol
,31161580,maximum possible treatment-related effect,"However, the Emax parameter was 2.5 times higher in the elderly and maximum possible treatment-related effect was 169 (135-221) in the young and 194 (149-252) in the elderly; that is, 15% higher in the elderly.",Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31161580/),,194,27700,DB00193,Tramadol
,23497674,Cmax,Tramadol reached higher concentrations after i.p. injection in diabetics (Cmax of 1607.5 ± 335.9 ng/ml) compared with control group (Cmax of 561.6 ± 111.4).,Study of the pharmacokinetic changes of Tramadol in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497674/),[ng] / [ml],1607.5,31486,DB00193,Tramadol
,23497674,Cmax,Tramadol reached higher concentrations after i.p. injection in diabetics (Cmax of 1607.5 ± 335.9 ng/ml) compared with control group (Cmax of 561.6 ± 111.4).,Study of the pharmacokinetic changes of Tramadol in diabetic rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23497674/),,561.6,31487,DB00193,Tramadol
,15509185,bioavailability,"Sustained-release tablets release the active ingredient over a period of 12 hours, reach peak concentrations after 4.9 hours and have a bioavailability of 87-95% compared with capsules.",Clinical pharmacology of tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,87-95,35613,DB00193,Tramadol
,15509185,plasma protein binding,Tramadol is rapidly distributed in the body; plasma protein binding is about 20%.,Clinical pharmacology of tramadol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),%,20,35614,DB00193,Tramadol
,15509185,elimination half-life,The mean elimination half-life is about 6 hours.,Clinical pharmacology of tramadol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509185/),h,6,35615,DB00193,Tramadol
,27541716,Plasma areas under the concentration-time curves,"Plasma areas under the concentration-time curves of (+)O-desmethyltramadol were 111.8 (95% confidence interval: 63.4-160.1), 80.2 (65.1-95.3), and 64.5 (51.9-77.2) h·ng·mL in carriers of 0, 1, or 2 active OCT1 alleles (P = 0.03).",Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541716/),h·ml·ng,111.8,38831,DB00193,Tramadol
,27541716,Plasma areas under the concentration-time curves,"Plasma areas under the concentration-time curves of (+)O-desmethyltramadol were 111.8 (95% confidence interval: 63.4-160.1), 80.2 (65.1-95.3), and 64.5 (51.9-77.2) h·ng·mL in carriers of 0, 1, or 2 active OCT1 alleles (P = 0.03).",Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541716/),h·ml·ng,80.2,38832,DB00193,Tramadol
,27541716,Plasma areas under the concentration-time curves,"Plasma areas under the concentration-time curves of (+)O-desmethyltramadol were 111.8 (95% confidence interval: 63.4-160.1), 80.2 (65.1-95.3), and 64.5 (51.9-77.2) h·ng·mL in carriers of 0, 1, or 2 active OCT1 alleles (P = 0.03).",Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541716/),h·ml·ng,64.5,38833,DB00193,Tramadol
,4019697,detection limit,The detection limit was about 4 ng/ml for serum samples of 1 ml.,Quantitative determination of tramadol in human serum by gas chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4019697/),[ng] / [ml],4,39174,DB00193,Tramadol
,18177319,apparent volume of distribution of the central compartment,"After i.v. administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20.8+/-3.2 mL/min/kg, and 134+/-18 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),[ml] / [kg],1553,40420,DB00193,Tramadol
,18177319,apparent volume of distribution at steady-state,"After i.v. administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20.8+/-3.2 mL/min/kg, and 134+/-18 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),[ml] / [kg],3103,40421,DB00193,Tramadol
,18177319,apparent volume of distribution at steady-state,"After i.v. administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20.8+/-3.2 mL/min/kg, and 134+/-18 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),[ml] / [kg·min],20.8,40422,DB00193,Tramadol
,18177319,clearance,"After i.v. administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20.8+/-3.2 mL/min/kg, and 134+/-18 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),[ml] / [kg],3103,40423,DB00193,Tramadol
,18177319,terminal half-life,"After i.v. administration, the apparent volume of distribution of the central compartment, the apparent volume of distribution at steady-state, the clearance, and the terminal half-life (mean +/- SEM) were 1553+/-118 mL/kg, 3103+/-132 mL/kg, 20.8+/-3.2 mL/min/kg, and 134+/-18 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),min,134,40424,DB00193,Tramadol
,18177319,Systemic availability,"Systemic availability and terminal half-life after oral administration were 93+/-7% and 204+/-8 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),%,93,40425,DB00193,Tramadol
,18177319,terminal half-life,"Systemic availability and terminal half-life after oral administration were 93+/-7% and 204+/-8 min, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),min,204,40426,DB00193,Tramadol
,18177319,terminal half-lives,"O-desmethyl-tramadol rapidly appeared in plasma following tramadol administration and had terminal half-lives of 261+/-28 and 289+/-19 min after i.v. and oral tramadol administration, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),min,261,40427,DB00193,Tramadol
,18177319,terminal half-lives,"O-desmethyl-tramadol rapidly appeared in plasma following tramadol administration and had terminal half-lives of 261+/-28 and 289+/-19 min after i.v. and oral tramadol administration, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),min,289,40428,DB00193,Tramadol
,18177319,rate of formation,"The rate of formation of O-desmethyl-tramadol estimated from a model including both tramadol and O-desmethyl-tramadol was 0.014+/-0.003/min and 0.004+/-0.0008/min after i.v. and oral tramadol administration, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),1/[min],0.014,40429,DB00193,Tramadol
,18177319,rate of formation,"The rate of formation of O-desmethyl-tramadol estimated from a model including both tramadol and O-desmethyl-tramadol was 0.014+/-0.003/min and 0.004+/-0.0008/min after i.v. and oral tramadol administration, respectively.","Pharmacokinetics of tramadol, and its metabolite O-desmethyl-tramadol, in cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177319/),1/[min],0.004,40430,DB00193,Tramadol
,10442207,bioavailability,As a result of the statistical analysis of AUCss(48-72 h) after logarithmic transformation a bioavailability of 100% for the sustained release capsules compared with the instant release capsules was obtained.,Pharmacokinetic properties of tramadol sustained release capsules. 3rd communication: investigation of relative bioavailability under steady state conditions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10442207/),%,100,41897,DB00193,Tramadol
,23331900,brain uptake clearances,"The brain uptake clearances of tramadol in Pgp-inhibited and control rats were 2.47±0.56 and 2.34±0.56 ml min(-1)g(-1), respectively, for 1 mg/kg and 3.50±0.60 and 3.14±1.02 mlmin(-1)g(-1), respectively, for 10 mg/kg dose.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),[ml] / [min],2.47,42281,DB00193,Tramadol
,23331900,brain uptake clearances,"The brain uptake clearances of tramadol in Pgp-inhibited and control rats were 2.47±0.56 and 2.34±0.56 ml min(-1)g(-1), respectively, for 1 mg/kg and 3.50±0.60 and 3.14±1.02 mlmin(-1)g(-1), respectively, for 10 mg/kg dose.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),[ml] / [min],2.34,42282,DB00193,Tramadol
,23331900,brain uptake clearances,"The brain uptake clearances of tramadol in Pgp-inhibited and control rats were 2.47±0.56 and 2.34±0.56 ml min(-1)g(-1), respectively, for 1 mg/kg and 3.50±0.60 and 3.14±1.02 mlmin(-1)g(-1), respectively, for 10 mg/kg dose.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),1/[mlmin],3.50,42283,DB00193,Tramadol
,23331900,brain uptake clearances,"The brain uptake clearances of tramadol in Pgp-inhibited and control rats were 2.47±0.56 and 2.34±0.56 ml min(-1)g(-1), respectively, for 1 mg/kg and 3.50±0.60 and 3.14±1.02 mlmin(-1)g(-1), respectively, for 10 mg/kg dose.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),1/[mlmin],3.14,42284,DB00193,Tramadol
more,23331900,"brain-to-plasma concentration ratio (Kp,app)","The brain-to-plasma concentration ratio (Kp,app) of more than 1 in all the time points following both the high and low dose cases (sometimes more than 3) indicated the brain accumulation of the drug.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),,1,42285,DB00193,Tramadol
more,23331900,"brain-to-plasma concentration ratio (Kp,app)","The brain-to-plasma concentration ratio (Kp,app) of more than 1 in all the time points following both the high and low dose cases (sometimes more than 3) indicated the brain accumulation of the drug.","Lack of evidence for involvement of P-glycoprotein in brain uptake of the centrally acting analgesic, tramadol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331900/),,3,42286,DB00193,Tramadol
,18585190,flow rate,The flow rate was 1 ml/min at the column temperature 45 degrees C.,Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),[ml] / [min],1,43213,DB00193,Tramadol
,18585190,retention times,"In these chromatographic conditions, the retention times were 2.3 min for O-desmethyltramadol and 3.5 min for tramadol, respectively.",Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),min,2.3,43214,DB00193,Tramadol
,18585190,retention times,"In these chromatographic conditions, the retention times were 2.3 min for O-desmethyltramadol and 3.5 min for tramadol, respectively.",Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),min,3.5,43215,DB00193,Tramadol
,18585190,m/z,The monitored ions were m/z 264 for tramadol and m/z 250 for its metabolite.,Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),,264,43216,DB00193,Tramadol
,18585190,m/z,The monitored ions were m/z 264 for tramadol and m/z 250 for its metabolite.,Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),,250,43217,DB00193,Tramadol
,18585190,recovery,The mean recovery for both analytes was 96%.,Determination of tramadol and O-desmethyltramadol in human plasma by high-performance liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18585190/),%,96,43218,DB00193,Tramadol
,10235420,t(max),"After i.m. injection the serum concentration peaks were reached after t(max) = 0.75 (0.25, 1.50) h and amounted to c(max) = 166 (1.24) ng/ml; the corresponding results after i.v. infusion were t(max) = 0.50 (0.33, 1.50) h and c(max) = 293 (1.35) ng/ml.",Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235420/),h,0.75,44412,DB00193,Tramadol
,10235420,c(max),"After i.m. injection the serum concentration peaks were reached after t(max) = 0.75 (0.25, 1.50) h and amounted to c(max) = 166 (1.24) ng/ml; the corresponding results after i.v. infusion were t(max) = 0.50 (0.33, 1.50) h and c(max) = 293 (1.35) ng/ml.",Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235420/),[ng] / [ml],166,44413,DB00193,Tramadol
,10235420,t(max),"After i.m. injection the serum concentration peaks were reached after t(max) = 0.75 (0.25, 1.50) h and amounted to c(max) = 166 (1.24) ng/ml; the corresponding results after i.v. infusion were t(max) = 0.50 (0.33, 1.50) h and c(max) = 293 (1.35) ng/ml.",Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235420/),h,0.50,44414,DB00193,Tramadol
,10235420,c(max),"After i.m. injection the serum concentration peaks were reached after t(max) = 0.75 (0.25, 1.50) h and amounted to c(max) = 166 (1.24) ng/ml; the corresponding results after i.v. infusion were t(max) = 0.50 (0.33, 1.50) h and c(max) = 293 (1.35) ng/ml.",Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235420/),[ng] / [ml],293,44415,DB00193,Tramadol
,26947771,apparent total clearances,"The apparent total clearances were 44.9 (19.1-102-2) L/h and 55.2 (14.8-126.0) L/h for (+)- and (-)-tramadol, respectively [data presented as median (minimum-maximum)].","Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947771/),[l] / [h],44.9,45774,DB00193,Tramadol
,26947771,apparent total clearances,"The apparent total clearances were 44.9 (19.1-102-2) L/h and 55.2 (14.8-126.0) L/h for (+)- and (-)-tramadol, respectively [data presented as median (minimum-maximum)].","Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26947771/),[l] / [h],55.2,45775,DB00193,Tramadol
,11092587,recoveries,The recoveries were around 90% for both T and ODT.,Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11092587/),%,90,46275,DB00193,Tramadol
,24717054,area under the curve plasma concentration versus time (AUC∞ ),The plasma concentrations of the active (+)-M1 were significantly reduced in T1DM (area under the curve plasma concentration versus time (AUC∞ ): 313.1 ng·h/ml) when compared with nondiabetic patients (AUC∞ : 1246.6 ng·h/ml).,Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24717054/),[h·ng] / [ml],313.1,51510,DB00193,Tramadol
,24717054,AUC∞,The plasma concentrations of the active (+)-M1 were significantly reduced in T1DM (area under the curve plasma concentration versus time (AUC∞ ): 313.1 ng·h/ml) when compared with nondiabetic patients (AUC∞ : 1246.6 ng·h/ml).,Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24717054/),[h·ng] / [ml],1246.6,51511,DB00193,Tramadol
,9638309,absolute bioavailability (F),"The extent of the absolute bioavailability (F) of tramadol after oral administration of the drops, based on AUC data, was 66.3% (point estimate; n = 8) with a 95% confidence interval of 58.1-75.6% (ANOVAlog).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),%,66.3,51729,DB00193,Tramadol
,9638309,areas under the serum concentration curves,"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],2390,51730,DB00193,Tramadol
,9638309,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],2390,51731,DB00193,Tramadol
,9638309,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2390 +/- 712 h.ng/ml (p.o.) and 3490 +/- 510 h.ng/ml (i.v.) (mean +/- SD; n = 8).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[h·ng] / [ml],3490,51732,DB00193,Tramadol
,9638309,cmax,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ng] / [ml],308,51733,DB00193,Tramadol
,9638309,tmax,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.20,51734,DB00193,Tramadol
,9638309,half-life of absorption,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.34,51735,DB00193,Tramadol
,9638309,"t1/2,ka","After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.34,51736,DB00193,Tramadol
,9638309,lag time,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.23,51737,DB00193,Tramadol
,9638309,t0,"After oral administration the means of the serum concentration peaks were 308 +/- 89 ng/ml (cmax) and 1.20 +/- 0.39 h (tmax), the half-life of absorption was 0.34 +/- 0.18 h (t1/2,ka) and the lag time 0.23 +/- 0.01 h (t0).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,0.23,51738,DB00193,Tramadol
,9638309,"biological half-life in the terminal phase (t1/2,beta)","The biological half-life in the terminal phase (t1/2,beta) was 5.5 +/- 0.9 h and agreed well with the value of 5.2 +/- 0.8 h determined after i.v. injection.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,5.5,51739,DB00193,Tramadol
,9638309,"biological half-life in the terminal phase (t1/2,beta)","The biological half-life in the terminal phase (t1/2,beta) was 5.5 +/- 0.9 h and agreed well with the value of 5.2 +/- 0.8 h determined after i.v. injection.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,5.2,51740,DB00193,Tramadol
,9638309,"distribution half-life (t1/2,alpha)","For the slower distribution half-life (t1/2,alpha) mean values of 1.2 +/- 0.7 h (p.o.; n = 6) and 1.9 +/- 0.7 h (i.v.; n = 6) were obtained.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.2,51741,DB00193,Tramadol
,9638309,"distribution half-life (t1/2,alpha)","For the slower distribution half-life (t1/2,alpha) mean values of 1.2 +/- 0.7 h (p.o.; n = 6) and 1.9 +/- 0.7 h (i.v.; n = 6) were obtained.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),h,1.9,51742,DB00193,Tramadol
,9638309,total distribution volume,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),l,216,51743,DB00193,Tramadol
,9638309,Cltot,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ml] / [min],487,51744,DB00193,Tramadol
,9638309,Clren,"The values determined after i.v. injection for the total distribution volume and the total and renal clearance were 216 +/- 21 l (Vd,beta), 487 +/- 71 ml/min (Cltot) and 77 +/- 20 ml/min (Clren), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638309/),[ml] / [min],77,51745,DB00193,Tramadol
,25488714,clearance,Tramadol clearance was 24.5 (23.4-32.7) mL/min/kg.,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),[ml] / [kg·min],24.5,56745,DB00193,Tramadol
,25488714,Terminal half-life,Terminal half-life of tramadol was 111 (106-127) min IV and 133 (84.9-198) min PO.,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),min,111,56746,DB00193,Tramadol
,25488714,Terminal half-life,Terminal half-life of tramadol was 111 (106-127) min IV and 133 (84.9-198) min PO.,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),min,133,56747,DB00193,Tramadol
,25488714,Bioavailability,Bioavailability of tramadol was poor [3.47% (2.14-5.96%)].,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),%,3.47,56748,DB00193,Tramadol
,25488714,Maximum serum concentration,Maximum serum concentration of M1 was 2.28 (1.88-2.73) ng/mL IV and 11.2 (9.37-14.9) ng/mL PO.,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),[ng] / [ml],2.28,56749,DB00193,Tramadol
,25488714,Maximum serum concentration,Maximum serum concentration of M1 was 2.28 (1.88-2.73) ng/mL IV and 11.2 (9.37-14.9) ng/mL PO.,Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488714/),[ng] / [ml],11.2,56750,DB00193,Tramadol
,9793614,absolute bioavailability (F),"The extent of the absolute bioavailability (F) of tramadol in the suppositories, based on AUC data, was 77.0% (point estimate; n = 10) with a 95% confidence interval of 70.8-83.6% (ANOVAlog).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),%,77.0,57675,DB00193,Tramadol
,9793614,areas under the serum concentration curves,"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2933 +/- 304 h.ng/ml (rectal) and 3775 +/- 446 h.ng/ml (i.v.) [mean +/- SD; n = 10].",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),[h·ng] / [ml],2933,57676,DB00193,Tramadol
,9793614,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2933 +/- 304 h.ng/ml (rectal) and 3775 +/- 446 h.ng/ml (i.v.) [mean +/- SD; n = 10].",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),[h·ng] / [ml],2933,57677,DB00193,Tramadol
,9793614,areas (AUC),"The areas under the serum concentration curves of tramadol-HCl calculated by curve fitting (AUC), which agreed very well with the model-independently determined areas (AUC), were 2933 +/- 304 h.ng/ml (rectal) and 3775 +/- 446 h.ng/ml (i.v.) [mean +/- SD; n = 10].",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),[h·ng] / [ml],3775,57678,DB00193,Tramadol
,9793614,t1/2,"Under this premise the absorption half-lives were t1/2,ka;1 = 1.7 h (median; range: 1.1-3.1 h) and t1/2,ka;2 = 0.98 h (0.35-1.9 h), and the corresponding lag times were t0;1 = 0 h (0-0.37 h) and t0;2 = 0.66 h (0.31-3.5 h).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,1.7,57679,DB00193,Tramadol
,9793614,"t1/2,ka;2","Under this premise the absorption half-lives were t1/2,ka;1 = 1.7 h (median; range: 1.1-3.1 h) and t1/2,ka;2 = 0.98 h (0.35-1.9 h), and the corresponding lag times were t0;1 = 0 h (0-0.37 h) and t0;2 = 0.66 h (0.31-3.5 h).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,0.98,57680,DB00193,Tramadol
,9793614,lag,"Under this premise the absorption half-lives were t1/2,ka;1 = 1.7 h (median; range: 1.1-3.1 h) and t1/2,ka;2 = 0.98 h (0.35-1.9 h), and the corresponding lag times were t0;1 = 0 h (0-0.37 h) and t0;2 = 0.66 h (0.31-3.5 h).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,0,57681,DB00193,Tramadol
,9793614,t0;1,"Under this premise the absorption half-lives were t1/2,ka;1 = 1.7 h (median; range: 1.1-3.1 h) and t1/2,ka;2 = 0.98 h (0.35-1.9 h), and the corresponding lag times were t0;1 = 0 h (0-0.37 h) and t0;2 = 0.66 h (0.31-3.5 h).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,0,57682,DB00193,Tramadol
,9793614,t0;2,"Under this premise the absorption half-lives were t1/2,ka;1 = 1.7 h (median; range: 1.1-3.1 h) and t1/2,ka;2 = 0.98 h (0.35-1.9 h), and the corresponding lag times were t0;1 = 0 h (0-0.37 h) and t0;2 = 0.66 h (0.31-3.5 h).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,0.66,57683,DB00193,Tramadol
,9793614,Cmax,The maxima of the serum concentration curves were reached 2-6 h after rectal administration; the means of the individual maxima were 294 +/- 50 ng/ml (Cmax) and 3.3 +/- 1.3 h (tmax).,Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),[ng] / [ml],294,57684,DB00193,Tramadol
,9793614,tmax,The maxima of the serum concentration curves were reached 2-6 h after rectal administration; the means of the individual maxima were 294 +/- 50 ng/ml (Cmax) and 3.3 +/- 1.3 h (tmax).,Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,3.3,57685,DB00193,Tramadol
,9793614,"half-life of the slower distribution (t1/2, alpha)","The means of the half-life of the slower distribution (t1/2, alpha) were 1.38 +/- 0.47 h (rectal; n = 10) and 1.78 +/- 0.63 h (i.v.; n = 7).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,1.38,57686,DB00193,Tramadol
,9793614,"half-life of the slower distribution (t1/2, alpha)","The means of the half-life of the slower distribution (t1/2, alpha) were 1.38 +/- 0.47 h (rectal; n = 10) and 1.78 +/- 0.63 h (i.v.; n = 7).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,1.78,57687,DB00193,Tramadol
,9793614,"biological half-life (t1/2, beta)","In the terminal phase the biological half-life (t1/2, beta) was 5.7 +/- 1.0 h (rectal) and 5.7 +/- 0.9 h (i.v.), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,5.7,57688,DB00193,Tramadol
,9793614,"biological half-life (t1/2, beta)","In the terminal phase the biological half-life (t1/2, beta) was 5.7 +/- 1.0 h (rectal) and 5.7 +/- 0.9 h (i.v.), respectively.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),h,5.7,57689,DB00193,Tramadol
,9793614,total distribution volume,"The values determined after i.v. injection for the total distribution volume and the total clearance were 216 +/- 231 (Vd, beta) and 447 +/- 56 ml/min (Cltot).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),,216,57690,DB00193,Tramadol
,9793614,"Vd, beta","The values determined after i.v. injection for the total distribution volume and the total clearance were 216 +/- 231 (Vd, beta) and 447 +/- 56 ml/min (Cltot).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),,216,57691,DB00193,Tramadol
,9793614,Cltot,"The values determined after i.v. injection for the total distribution volume and the total clearance were 216 +/- 231 (Vd, beta) and 447 +/- 56 ml/min (Cltot).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9793614/),[ml] / [min],447,57692,DB00193,Tramadol
,33280136,AUC,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],"2,663",63673,DB00193,Tramadol
,33280136,AUC,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],"2,964",63674,DB00193,Tramadol
,33280136,AUC,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],378,63675,DB00193,Tramadol
,33280136,AUC,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],345,63676,DB00193,Tramadol
,33280136,T,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],378,63677,DB00193,Tramadol
,33280136,T,"However, the pharmacokinetic parameter calculation corrected by dose analysis identified no proportional increase with dose for the AUC of tramadol (T2: 2,663 ± 1,827 vs. T4: 2,964 ± 1,038 ng*h/ml) and M1 (T2: 378 ± 237 vs. T4: 345 ± 142 ng*h/ml).",Pharmacokinetic properties of tramadol and M1 metabolite in Northeast Brazilian donkeys (Equus asinus). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33280136/),[h·ng] / [ml],345,63678,DB00193,Tramadol
,30825803,flow rate,"In this study, a reversed-phase chromatography was performed at room temperature on a C18 column with a mobile phase composed of 10 mM Na2HPO4 solution (pH 7.5): acetonitrile (45:55, v/v) at a flow rate of 0.8 mL min-1 using caffeine (CAF) as an internal standard.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[ml] / [min],0.8,66387,DB00193,Tramadol
,30825803,total analysis time,The total analysis time was 6 min.,Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),min,6,66388,DB00193,Tramadol
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.05,66389,DB00193,Tramadol
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.02,66390,DB00193,Tramadol
,3778568,absolute bioavailability,The absolute bioavailability of tramadol in Tramal capsules was 68 +/- 13% (means +/- SD; n = 10) with a range of 41-84% and a 95% confidence interval of 55.0-79.2%.,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),%,68,66443,DB00193,Tramadol
,3778568,areas under the serum concentration curves of tramadol hydrochloride (AUC),The areas under the serum concentration curves of tramadol hydrochloride (AUC) were 2488 +/- 774 ng X h/ml (p.o.) and 3709 +/- 977 ng X h/ml (i.v.).,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),[h·ng] / [ml],2488,66444,DB00193,Tramadol
,3778568,areas under the serum concentration curves of tramadol hydrochloride (AUC),The areas under the serum concentration curves of tramadol hydrochloride (AUC) were 2488 +/- 774 ng X h/ml (p.o.) and 3709 +/- 977 ng X h/ml (i.v.).,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),[h·ng] / [ml],3709,66445,DB00193,Tramadol
,3778568,Peak serum concentrations,Peak serum concentrations of 280 +/- 49 ng/ml were reached 2 h after oral administration of two Tramal capsules; a serum concentration of 100 ng/ml (assumed as the threshold value for analgesic efficacy) was reached after 0.68 +/- 0.17 h and was maintained for 9.0 +/- 2.2 h.,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),[ng] / [ml],280,66446,DB00193,Tramadol
,3778568,half-life of absorption,The half-life of absorption was 0.38 +/- 0.18 h and the lag-time 0.48 +/- 0.14 h.,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),h,0.38,66447,DB00193,Tramadol
,3778568,lag-time,The half-life of absorption was 0.38 +/- 0.18 h and the lag-time 0.48 +/- 0.14 h.,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),h,0.48,66448,DB00193,Tramadol
,3778568,biological half-lives,In the terminal phase the biological half-lives of tramadol were 5.1 +/- 0.8 h (p.o.) and 5.2 +/- 0.8 h (i.v.).,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),h,5.1,66449,DB00193,Tramadol
,3778568,biological half-lives,In the terminal phase the biological half-lives of tramadol were 5.1 +/- 0.8 h (p.o.) and 5.2 +/- 0.8 h (i.v.).,Bioavailability of enteral tramadol formulations. 1st communication: capsules. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778568/),h,5.2,66450,DB00193,Tramadol
,22428763,VAS2h,Mean VAS2h value in the whole study group was 44.0 ± 16.5 mm.,Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22428763/),mm,44.0,66465,DB00193,Tramadol
,22428763,consumption,Mean tramadol consumption was 2.47 ± 1.17 mg/kg during the 24 h period.,Tramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22428763/),,2.47,66466,DB00193,Tramadol
,25888861,first Tramadol concentration,"Serum Tramadol levels: Mean (SD, min-max) first Tramadol concentration was 786.91 (394.53, 391-1495).",Tramadol half life is dose dependent in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888861/),min,786.91,70624,DB00193,Tramadol
,25888861,second,"Mean (SD, min-max) second Tramadol concentration was 433.09 (269.63, 148-950).",Tramadol half life is dose dependent in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888861/),min,433.09,70625,DB00193,Tramadol
,25888861,Tramadol concentration,"Mean (SD, min-max) second Tramadol concentration was 433.09 (269.63, 148-950).",Tramadol half life is dose dependent in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888861/),min,433.09,70626,DB00193,Tramadol
,25888861,half life,"Mean (SD, min-max) of Tramadol half life was calculated as 9.24 hour (2.310, 4.99-13.45) Associations: Half life was associated with higher concentrations (r=0.708 Sig=0.015).",Tramadol half life is dose dependent in overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888861/),h,9.24,70627,DB00193,Tramadol
,25888861,half life,We report the mean half life of tramadol in overdose to be 9.24 hours which is remarkably higher than that measured in previous pharmacokinetic studies.,Tramadol half life is dose dependent in overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25888861/),h,9.24,70628,DB00193,Tramadol
,19521463,absolute bioavailability,The absolute bioavailability of tramadol via rectal administration was 10 (SD 4)%.,Pharmacokinetics of tramadol and its major metabolites following rectal and intravenous administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19521463/),%,10,71312,DB00193,Tramadol
,30986883,F (Fraction absorbed),"After p.o. administration (30 mg/kg) of JW5473, F (Fraction absorbed) value was approximately 70.5%.",Determination of JW5473 in Rat Plasma by UPLC-MS/MS and its Application to Pharmacokinetic Study of JW5473. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30986883/),%,70.5,73246,DB00193,Tramadol
,19070266,therapeutic threshold concentration,"The results of this exploratory study suggest that similar to immediate-release tramadol, onset of analgesia for this controlled-release formulation of tramadol (Tramadol Contramid OAD) occurs within 1 hour at a mean therapeutic threshold concentration of 56 +/- 38 ng/mL.",Onset of analgesic effect and plasma levels of controlled-release tramadol (Tramadol Contramid once-a-day) 200-mg tablets in patients with acute low back pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070266/),[ng] / [ml],56,73931,DB00193,Tramadol
,32209370,absolute bioavailability,"The plasma and CSF absolute bioavailability values were 1.09 and 0.87, respectively.",A new nanovesicular system for nasal drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32209370/),,1.09,75372,DB00193,Tramadol
,32209370,absolute bioavailability,"The plasma and CSF absolute bioavailability values were 1.09 and 0.87, respectively.",A new nanovesicular system for nasal drug administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32209370/),,0.87,75373,DB00193,Tramadol
,25362810,f2,Both TP and TR formulations showed a similar release profile of TH (f2 was 71) in in vitro release studies.,Biopharmaceutical evaluation of new slow release tablets obtained by hot tableting of coated pellets with tramadol hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25362810/),,71,75692,DB00193,Tramadol
,27138295,terminal elimination t1/2,The arithmetic mean terminal elimination t1/2 of tramadol in children and adolescents was comparable to that in adults (children 8.4 hours; adolescents 8.5 hours; adults 7.9 hours).,Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and Adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138295/),h,8.4,77728,DB00193,Tramadol
,27138295,terminal elimination t1/2,The arithmetic mean terminal elimination t1/2 of tramadol in children and adolescents was comparable to that in adults (children 8.4 hours; adolescents 8.5 hours; adults 7.9 hours).,Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and Adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138295/),h,8.5,77729,DB00193,Tramadol
,27138295,terminal elimination t1/2,The arithmetic mean terminal elimination t1/2 of tramadol in children and adolescents was comparable to that in adults (children 8.4 hours; adolescents 8.5 hours; adults 7.9 hours).,Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and Adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138295/),h,7.9,77730,DB00193,Tramadol
,16007420,concentrations at the time of birth (t(0)),"Serum tramadol concentrations at the time of birth (t(0)) were 243+/-102 ng/ml (mean+/-SD, umbilical vein), 258+/-103 ng/ml (umbilical artery) and 250+/-113 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],243,78488,DB00193,Tramadol
,16007420,concentrations at the time of birth (t(0)),"Serum tramadol concentrations at the time of birth (t(0)) were 243+/-102 ng/ml (mean+/-SD, umbilical vein), 258+/-103 ng/ml (umbilical artery) and 250+/-113 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],258,78489,DB00193,Tramadol
,16007420,concentrations at the time of birth (t(0)),"Serum tramadol concentrations at the time of birth (t(0)) were 243+/-102 ng/ml (mean+/-SD, umbilical vein), 258+/-103 ng/ml (umbilical artery) and 250+/-113 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],250,78490,DB00193,Tramadol
,16007420,Serum M1 concentrations,"Serum M1 concentrations were 52+/-27 ng/ml (umbilical vein), 47+/-24 ng/ml (umbilical artery) and 56+/-21 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],52,78491,DB00193,Tramadol
,16007420,Serum M1 concentrations,"Serum M1 concentrations were 52+/-27 ng/ml (umbilical vein), 47+/-24 ng/ml (umbilical artery) and 56+/-21 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],47,78492,DB00193,Tramadol
,16007420,Serum M1 concentrations,"Serum M1 concentrations were 52+/-27 ng/ml (umbilical vein), 47+/-24 ng/ml (umbilical artery) and 56+/-21 ng/ml (maternal vein).",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),[ng] / [ml],56,78493,DB00193,Tramadol
,16007420,terminal t(1/2),"The two-compartment type elimination profiles during the first 12 h post-partum for neonates (and mothers, respectively) were characterised by terminal t(1/2) (tramadol)=7.0 (7.2) h and t(1/2) (metabolite M1)=85.0 (5.5) h.",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),h,7.0,78494,DB00193,Tramadol
,16007420,t(1/2),"The two-compartment type elimination profiles during the first 12 h post-partum for neonates (and mothers, respectively) were characterised by terminal t(1/2) (tramadol)=7.0 (7.2) h and t(1/2) (metabolite M1)=85.0 (5.5) h.",Different pharmacokinetics of tramadol in mothers treated for labour pain and in their neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16007420/),h,85.0,78495,DB00193,Tramadol
,18177318,retention time,Average retention time was 5.13 min for tramadol and 2.42 min for M1.,Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),min,5.13,78550,DB00193,Tramadol
,18177318,retention time,Average retention time was 5.13 min for tramadol and 2.42 min for M1.,Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),min,2.42,78551,DB00193,Tramadol
,18177318,half-life,"The calculated parameters for half-life, volume of distribution and total body clearance were 0.94+/-0.34 h, 2.48+/-0.58 L/kg and 2.18+/-0.23 L/kg/h following 2 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),h,0.94,78552,DB00193,Tramadol
,18177318,volume of distribution,"The calculated parameters for half-life, volume of distribution and total body clearance were 0.94+/-0.34 h, 2.48+/-0.58 L/kg and 2.18+/-0.23 L/kg/h following 2 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),[l] / [kg],2.48,78553,DB00193,Tramadol
,18177318,total body clearance,"The calculated parameters for half-life, volume of distribution and total body clearance were 0.94+/-0.34 h, 2.48+/-0.58 L/kg and 2.18+/-0.23 L/kg/h following 2 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),[l] / [h·kg],2.18,78554,DB00193,Tramadol
,18177318,systemic availability,The systemic availability was 36.9+/-9.1% and half-life 2.67+/-0.54 h following tramadol 2 mg/kg p.o. M1 had a half-life of 2.89+/-0.43 h following i.v. administration of tramadol.,Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),%,36.9,78555,DB00193,Tramadol
,18177318,half-life,The systemic availability was 36.9+/-9.1% and half-life 2.67+/-0.54 h following tramadol 2 mg/kg p.o. M1 had a half-life of 2.89+/-0.43 h following i.v. administration of tramadol.,Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),h,2.67,78556,DB00193,Tramadol
,18177318,half-life,The systemic availability was 36.9+/-9.1% and half-life 2.67+/-0.54 h following tramadol 2 mg/kg p.o. M1 had a half-life of 2.89+/-0.43 h following i.v. administration of tramadol.,Pharmacokinetics of tramadol and o-desmethyltramadol in goats after intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177318/),h,2.89,78557,DB00193,Tramadol
,25265827,f2,In vitro release study of both formulations showed a similar release profile of TH over 8 h (f2 was 52).,In vitro - in vivo evaluation of a new oral dosage form of tramadol hydrochloride--controlled-release capsules filled with coated pellets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265827/),,52,79994,DB00193,Tramadol
,30656715,Elimination half-life,"Elimination half-life was 3.95 hr for tramadol in ducks, which is similar to other avian species.",Pharmacokinetics of orally administered tramadol in Muscovy ducks (Cairina moschata domestica). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30656715/),h,3.95,80521,DB00193,Tramadol
,25832551,maximum plasma concentrations,"For 5 and 10 mg/kg bwt treatments, respectively, individual maximum plasma concentrations (μg/l) ranged from 329 to 728 and 628 to 1330 (tramadol), 12-24 and 32-80 (M1), and 90-157 and 239-362 (M2).","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[μg] / [l],329 to 728,84721,DB00193,Tramadol
,25832551,maximum plasma concentrations,"For 5 and 10 mg/kg bwt treatments, respectively, individual maximum plasma concentrations (μg/l) ranged from 329 to 728 and 628 to 1330 (tramadol), 12-24 and 32-80 (M1), and 90-157 and 239-362 (M2).","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[μg] / [l],628 to 1330,84722,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],727,84723,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],1426,84724,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],33,84725,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],88,84726,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],303,84727,DB00193,Tramadol
,25832551,area under the concentration vs. time curves,"Respective median area under the concentration vs. time curves (h μg/l) were 727 and 1426, 33 and 88, 303 and 1003.","Plasma concentrations, analgesic and physiological assessments in horses with chronic laminitis treated with two doses of oral tramadol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25832551/),[h·μg] / [l],1003,84728,DB00193,Tramadol
,16280260,flow rate,"Chromatographic separation was achieved with a Chromolith Performance RP-18e 50 mm x 4.6 mm column, using a mixture of methanol:water (13:87, v/v) adjusted to pH 2.5 by phosphoric acid, in an isocratic mode at flow rate of 2 ml/min.","Development and validation of a rapid HPLC method for simultaneous determination of tramadol, and its two main metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280260/),[ml] / [min],2,85200,DB00193,Tramadol
,16280260,lambda(ex),Fluorescence detection (lambda(ex)=200 nm/lambda(em)=301 nm) was used.,"Development and validation of a rapid HPLC method for simultaneous determination of tramadol, and its two main metabolites in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16280260/),,200,85201,DB00193,Tramadol
,27729987,total run time,The chromatographic total run time was 10 min.,Validated determination method of tramadol and its desmethylates in human plasma using an isocratic LC-MS/MS and its clinical application to patients with cancer pain or non-cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27729987/),min,10,87357,DB00193,Tramadol
,27729987,extraction recoveries,Their extraction recoveries were 85.5-106.3 %.,Validated determination method of tramadol and its desmethylates in human plasma using an isocratic LC-MS/MS and its clinical application to patients with cancer pain or non-cancer pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27729987/),%,85.5-106.3,87358,DB00193,Tramadol
,20166437,flow rate,"The analyte was separated on a Diamonsil C18 column with ammonium acetate (5 mmol x L(-1))-methanol (50:50,v:v) adjusted PH by caustic soda at a flow rate of 0.8 ml min(-1), and analyzed by mass spectrometry is in positive ion mode.",Development and validation of a sensitive LC-MS method for the determination of tramadol in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166437/),[ml] / [min],0.8,89597,DB00193,Tramadol
,20166437,ion mass spectrum,"The ion mass spectrum of m/z were 264.1 for Tramadol and 248.0 for Tinidazole (I.S.), respectively.",Development and validation of a sensitive LC-MS method for the determination of tramadol in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166437/),,264.1,89598,DB00193,Tramadol
,20166437,ion mass spectrum,"The ion mass spectrum of m/z were 264.1 for Tramadol and 248.0 for Tinidazole (I.S.), respectively.",Development and validation of a sensitive LC-MS method for the determination of tramadol in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166437/),,248.0,89599,DB00193,Tramadol
,15169737,Elimination half-life,Elimination half-life was 4.3 (0.2) h (sem) and the apparent clearance was 16.4 (1.5) litre h(-1) (sem).,Pharmacokinetics of rectal tramadol in postoperative paediatric patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15169737/),h,4.3,91365,DB00193,Tramadol
,15169737,apparent clearance,Elimination half-life was 4.3 (0.2) h (sem) and the apparent clearance was 16.4 (1.5) litre h(-1) (sem).,Pharmacokinetics of rectal tramadol in postoperative paediatric patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15169737/),[l] / [h],16.4,91366,DB00193,Tramadol
,16951997,apparent volumes of distribution of the central compartment,"The estimates of the apparent volumes of distribution of the central compartment and at steady state and total plasma clearance of T were 8 l, 46.2 l, and 15.2 l/h, respectively.",Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16951997/),l,8,95611,DB00193,Tramadol
,16951997,at steady state,"The estimates of the apparent volumes of distribution of the central compartment and at steady state and total plasma clearance of T were 8 l, 46.2 l, and 15.2 l/h, respectively.",Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16951997/),l,8,95612,DB00193,Tramadol
,16951997,at steady state,"The estimates of the apparent volumes of distribution of the central compartment and at steady state and total plasma clearance of T were 8 l, 46.2 l, and 15.2 l/h, respectively.",Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16951997/),l,46.2,95613,DB00193,Tramadol
,16951997,total plasma clearance,"The estimates of the apparent volumes of distribution of the central compartment and at steady state and total plasma clearance of T were 8 l, 46.2 l, and 15.2 l/h, respectively.",Population pharmacokinetic/pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16951997/),[l] / [h],15.2,95614,DB00193,Tramadol
<,30248201,clearance,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),[ml] / [kg·min],1,99196,DB00193,Tramadol
,30248201,milk-to-plasma concentration ratio,Drugs with low clearance (<1 mL/[kg·min]) are likely to cause an infant exposure level greater than 10% of the weight-adjusted maternal dose even if the milk-to-plasma concentration ratio is 1.,Opioids in Breast Milk: Pharmacokinetic Principles and Clinical Implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30248201/),,1,99197,DB00193,Tramadol
greater,10676987,recoveries,The recoveries of tramadol and meperidine (internal standard) were greater than 88%.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),%,88,99736,DB00193,Tramadol
,10676987,limit of detection,The limit of detection was 8 ng/ml of plasma based on signal-to-noise ratio of 3.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),[ng] / [ml],8,99737,DB00193,Tramadol
,10676987,signal-to-noise ratio,The limit of detection was 8 ng/ml of plasma based on signal-to-noise ratio of 3.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),,3,99738,DB00193,Tramadol
,10676987,distribution,The distribution and elimination half-lives in humans were 1.02 and 141.9 min.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,1.02,99739,DB00193,Tramadol
,10676987,elimination half-lives,The distribution and elimination half-lives in humans were 1.02 and 141.9 min.,Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,141.9,99740,DB00193,Tramadol
,10676987,distribution,"The distribution and elimination half-lives in rabbits were 7.31 and 63.2 min, respectively.",Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,7.31,99741,DB00193,Tramadol
,10676987,elimination half-lives,"The distribution and elimination half-lives in rabbits were 7.31 and 63.2 min, respectively.",Determination of tramadol by capillary gas chromatography with flame ionization detection. Application to human and rabbit pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10676987/),min,63.2,99742,DB00193,Tramadol
,15951326,Clearance,Clearance increased from 25 weeks post-conception age (PCA) (5.52 litre h(-1) [70 kg](-1)) to reach 84% of the mature value by 44 weeks PCA (standardized to a 70 kg adult using allometric '1/4 power' models).,Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951326/),[l] / [h],5.52,99898,DB00193,Tramadol
,15951326,central volume of distribution,The central volume of distribution decreased from 25 weeks PCA (256 litre [70 kg](-1)) to reach 120% of its mature value by 87 weeks PCA.,Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951326/),l,256,99899,DB00193,Tramadol
,27365222,Cmax (C0,"Our results demonstrate that the plasma values of Cmax (C0 in i.v. group) and area under the curve (AUC)0-t for tramadol were 23,314.40±6944.85 vs. 3187.39±760.25ng/mL (Cmax) and 871.15±165.98 vs. 414.04±149.25μg·min/mL in the i.v. and i.p. groups, respectively (p<0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),[ng] / [ml],"23,314.40",99924,DB00193,Tramadol
,27365222,area under the curve (AUC)0-t,"Our results demonstrate that the plasma values of Cmax (C0 in i.v. group) and area under the curve (AUC)0-t for tramadol were 23,314.40±6944.85 vs. 3187.39±760.25ng/mL (Cmax) and 871.15±165.98 vs. 414.04±149.25μg·min/mL in the i.v. and i.p. groups, respectively (p<0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),[ng] / [ml],3187.39,99925,DB00193,Tramadol
,27365222,Cmax,"Our results demonstrate that the plasma values of Cmax (C0 in i.v. group) and area under the curve (AUC)0-t for tramadol were 23,314.40±6944.85 vs. 3187.39±760.25ng/mL (Cmax) and 871.15±165.98 vs. 414.04±149.25μg·min/mL in the i.v. and i.p. groups, respectively (p<0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),[min·μg] / [ml],414.04,99926,DB00193,Tramadol
,27365222,AUC0-t,There was no significant difference between the AUC0-t of tramadol in plasma (414.04±149.25μg·min/mL) and CSF (221.81±83.02μg·min/mL) in the i.p. group.,Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),[min·μg] / [ml],414.04,99927,DB00193,Tramadol
,27365222,AUC0-t,There was no significant difference between the AUC0-t of tramadol in plasma (414.04±149.25μg·min/mL) and CSF (221.81±83.02μg·min/mL) in the i.p. group.,Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),[min·μg] / [ml],221.81,99928,DB00193,Tramadol
,27365222,"Kp,uu,CSF(0-360)","There were also no significant differences among the Kp,uu,CSF(0-360) (0.51±0.12 vs. 0.63±0.04) and Kp,uu,CSF(0-∞) (0.61±0.10 vs. 0.62±0.02) for i.v. and i.p. pathways, respectively (p>0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),,0.51,99929,DB00193,Tramadol
,27365222,"Kp,uu,CSF(0-360)","There were also no significant differences among the Kp,uu,CSF(0-360) (0.51±0.12 vs. 0.63±0.04) and Kp,uu,CSF(0-∞) (0.61±0.10 vs. 0.62±0.02) for i.v. and i.p. pathways, respectively (p>0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),,0.63,99930,DB00193,Tramadol
,27365222,"Kp,uu,CSF(0-∞)","There were also no significant differences among the Kp,uu,CSF(0-360) (0.51±0.12 vs. 0.63±0.04) and Kp,uu,CSF(0-∞) (0.61±0.10 vs. 0.62±0.02) for i.v. and i.p. pathways, respectively (p>0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),,0.61,99931,DB00193,Tramadol
,27365222,"Kp,uu,CSF(0-∞)","There were also no significant differences among the Kp,uu,CSF(0-360) (0.51±0.12 vs. 0.63±0.04) and Kp,uu,CSF(0-∞) (0.61±0.10 vs. 0.62±0.02) for i.v. and i.p. pathways, respectively (p>0.05).",Evaluation of the route dependency of the pharmacokinetics and neuro-pharmacokinetics of tramadol and its main metabolites in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27365222/),,0.62,99932,DB00193,Tramadol
,12790210,target plasma concentration,The propofol target plasma concentration was 1.2 microg mL(-1) throughout the procedure.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[μg] / [ml],1.2,100789,DB00193,Tramadol
,12790210,target plasma concentration,A remifentanil target plasma concentration of 8 ng mL(-1) was achieved over 2 min for induction.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[ng] / [ml],8,100790,DB00193,Tramadol
,12790210,time to extubation,The duration of postoperative mechanical ventilation of the lungs was 95 +/- 13 min and the time to extubation was 150 +/- 18 min.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),min,150,100791,DB00193,Tramadol
,26875837,volume of distribution (Vd),"The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),[l] / [kg],4.77,103921,DB00193,Tramadol
,26875837,"elimination half-life (t1/2,β)","The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),h,1.91,103922,DB00193,Tramadol
,26875837,"elimination half-life (t1/2,β)","The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),[l] / [kg],4.73,103923,DB00193,Tramadol
,26875837,"elimination half-life (t1/2,β)","The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),h,2.39,103924,DB00193,Tramadol
,26875837,total body clearance (CLtot),"The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),[ml] / [kg·min],29.9,103925,DB00193,Tramadol
,26875837,total body clearance (CLtot),"The volume of distribution (Vd), elimination half-life (t1/2,β) and total body clearance (CLtot) of the young group were 4.77 ± 1.07 l/kg, 1.91 ± 0.26 hr and 29.9 ± 7.3 ml/min/kg, respectively, while those of the middle-aged group were 4.73 ± 1.43 l/kg, 2.39 ± 0.97 hr and 23.7 ± 5.4 ml/min/kg, respectively.",Comparison of pharmacokinetics of tramadol between young and middle-aged dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26875837/),[ml] / [kg·min],23.7,103926,DB00193,Tramadol
>,29066180,Cmax,"After all administration routes, Cmax was >100 ng mL-1 for tramadol and >40 ng mL-1 for M1 (reported analgesic ranges in man) followed by short half-lives (2-6 hours).",Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066180/),[ng] / [ml],100,103932,DB00193,Tramadol
>,29066180,Cmax,"After all administration routes, Cmax was >100 ng mL-1 for tramadol and >40 ng mL-1 for M1 (reported analgesic ranges in man) followed by short half-lives (2-6 hours).",Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066180/),[ng] / [ml],40,103933,DB00193,Tramadol
,29066180,half-lives,"After all administration routes, Cmax was >100 ng mL-1 for tramadol and >40 ng mL-1 for M1 (reported analgesic ranges in man) followed by short half-lives (2-6 hours).",Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066180/),h,2-6,103934,DB00193,Tramadol
>,29066180,plasma concentration,The mean tramadol plasma concentration after self-administration remained >100 ng mL-1 throughout consumption time.,Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066180/),[ng] / [ml],100,103935,DB00193,Tramadol
,29066180,oral bioavailability,Tramadol had low oral bioavailability (26%).,Preliminary pharmacokinetics of tramadol hydrochloride after administration via different routes in male and female B6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29066180/),%,26,103936,DB00193,Tramadol
,10793594,elimination half-life,"After a single i.v. injection (n = 9), the mean elimination half-life of tramadol was 6.4 (SD 2.7) h, with a volume of distribution of 3.1 (1.1) litre kg-1 and total plasma clearance of 6.1 (2.5) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),h,6.4,106625,DB00193,Tramadol
,10793594,volume of distribution,"After a single i.v. injection (n = 9), the mean elimination half-life of tramadol was 6.4 (SD 2.7) h, with a volume of distribution of 3.1 (1.1) litre kg-1 and total plasma clearance of 6.1 (2.5) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),[l] / [kg],3.1,106626,DB00193,Tramadol
,10793594,total plasma clearance,"After a single i.v. injection (n = 9), the mean elimination half-life of tramadol was 6.4 (SD 2.7) h, with a volume of distribution of 3.1 (1.1) litre kg-1 and total plasma clearance of 6.1 (2.5) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),[ml] / [kg·min],6.1,106627,DB00193,Tramadol
,10793594,elimination half-life,"After caudal epidural administration (n = 5), mean elimination half-life was 3.7 (0.9) h, volume of distribution was 2.0 (0.4) litre kg-1 and total clearance was 6.6 (1.9) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),h,3.7,106628,DB00193,Tramadol
,10793594,volume of distribution,"After caudal epidural administration (n = 5), mean elimination half-life was 3.7 (0.9) h, volume of distribution was 2.0 (0.4) litre kg-1 and total clearance was 6.6 (1.9) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),[l] / [kg],2.0,106629,DB00193,Tramadol
,10793594,total clearance,"After caudal epidural administration (n = 5), mean elimination half-life was 3.7 (0.9) h, volume of distribution was 2.0 (0.4) litre kg-1 and total clearance was 6.6 (1.9) ml kg-1 min-1.",Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10793594/),[ml] / [kg·min],6.6,106630,DB00193,Tramadol
,20079994,flow rate,"Sample preparation by liquid-liquid extraction with diethyl ether-dichloromethane (60:40, v/v) was followed by chromatography on a Venusil MP-C18 column using methanol-ammonium acetate (10mM)-formic acid (pH 3.4) (50:50:0.05, v/v/v) at a flow rate of 0.8mL/min.",Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079994/),[ml] / [min],0.8,108680,DB00193,Tramadol
,17296459,pain intensity scores,"Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001).","Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296459/),mm,62.,112820,DB00193,Tramadol
,17296459,pain intensity scores,"Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001).","Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296459/),,23.,112821,DB00193,Tramadol
,17296459,pain intensity scores,"Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001).","Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296459/),,2,112822,DB00193,Tramadol
,17296459,pain intensity scores,"Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001).","Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296459/),mm,16.9,112823,DB00193,Tramadol
,17296459,pain intensity scores,"Overall, mean pain intensity scores, as measured using the VAS and NAS, were decreased from baseline (62.4 [2.0] mm and 6.22 [0.22] points, respectively) to steady state with tramadol IR (23.6 [2.9] mm and 2.65 [0.30] points) and tramadol SR (16.9 [2.5] mm and 1.91 [0.26] points) (all, P < 0.001).","Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296459/),,1,112824,DB00193,Tramadol
,17570739,total clearance (CL),The mean total clearance (CL) predicted by the model was lower (19 L/h) and the half-life longer (5.9 hours) than those reported in Western populations.,Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),[l] / [h],19,113014,DB00193,Tramadol
,17570739,half-life,The mean total clearance (CL) predicted by the model was lower (19 L/h) and the half-life longer (5.9 hours) than those reported in Western populations.,Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),h,5.9,113015,DB00193,Tramadol
,17570739,CL,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),[l] / [h],16,113016,DB00193,Tramadol
,17570739,CL,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),[l] / [h],18,113017,DB00193,Tramadol
,17570739,CL,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),[l] / [h],23,113018,DB00193,Tramadol
,17570739,CL,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),[l] / [h],42,113019,DB00193,Tramadol
,17570739,half-lives,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),h,7.1,113020,DB00193,Tramadol
,17570739,half-lives,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),h,6.8,113021,DB00193,Tramadol
,17570739,half-lives,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),h,5.6,113022,DB00193,Tramadol
,17570739,half-lives,"CL was 16, 18, 23, and 42 L/h while mean half-lives were 7.1, 6.8, 5.6, and 3.8 hours among the IM, EM1, EM2, and UM groups, respectively.",Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17570739/),h,3.8,113023,DB00193,Tramadol
,11876441,AUC(0-infinity),"Values of 1,226.4 ng h/ml (Tramadol) and 1,397.01 ng x h/ml (Tramal) for the parameter AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[h·ng] / [ml],"1,226.4",116259,DB00193,Tramadol
,11876441,AUC(0-infinity),"Values of 1,226.4 ng h/ml (Tramadol) and 1,397.01 ng x h/ml (Tramal) for the parameter AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[h·ng] / [ml],"1,397.01",116260,DB00193,Tramadol
,11876441,Maximum concentrations--Cmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[ng] / [ml],217.81,116261,DB00193,Tramadol
,11876441,Maximum concentrations--Cmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[ng] / [ml],246.0,116262,DB00193,Tramadol
,11876441,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),h,2.14,116263,DB00193,Tramadol
,11876441,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),h,2.31,116264,DB00193,Tramadol
,17559753,Tmax,The Tmax for the reference (10-12 h) was significantly (p < 0.05) longer than that for the test (5-6 h).,Single- and multiple-dose bioequivalence of two once-daily tramadol formulations using stereospecific analysis of tramadol and its demethylated (M1 and M5) metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559753/),h,10-12,117344,DB00193,Tramadol
,17559753,Tmax,The Tmax for the reference (10-12 h) was significantly (p < 0.05) longer than that for the test (5-6 h).,Single- and multiple-dose bioequivalence of two once-daily tramadol formulations using stereospecific analysis of tramadol and its demethylated (M1 and M5) metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17559753/),h,5-6,117345,DB00193,Tramadol
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],263,118155,DB00193,Tramadol
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],346,118156,DB00193,Tramadol
,28810061,maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[ng] / [ml],349,118157,DB00193,Tramadol
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],3039,118158,DB00193,Tramadol
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],2979,118159,DB00193,Tramadol
,28810061,cumulative area under the plasma concentration-time curve,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),[h·ng] / [ml],3119,118160,DB00193,Tramadol
,28810061,time to maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),h,2.7,118161,DB00193,Tramadol
,28810061,time to maximum plasma concentration,"Tramadol PK parameters for Treatments-1, -2 and -4, respectively, were 263, 346 and 349 ng ml-1 (mean maximum plasma concentration); 3039, 2979 and 3119 ng h ml-1 (mean cumulative area under the plasma concentration-time curve); and 2.7, 1.8 and 1.8 h (median time to maximum plasma concentration).",Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: Results of a four-way randomized open-label phase I clinical trial in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810061/),h,1.8,118162,DB00193,Tramadol
,17913403,M1G/M1total,"Mean M1G/M1total was 27 (SD 15) % and was significantly lower in early compared to late neonatal life (22 versus 32%, p=0.0001).",Both postnatal and postmenstrual age contribute to the interindividual variability in tramadol glucuronidation in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17913403/),%,27,118942,DB00193,Tramadol
,17913403,M1G/M1total,"Mean M1G/M1total was 27 (SD 15) % and was significantly lower in early compared to late neonatal life (22 versus 32%, p=0.0001).",Both postnatal and postmenstrual age contribute to the interindividual variability in tramadol glucuronidation in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17913403/),%,22,118943,DB00193,Tramadol
,17913403,M1G/M1total,"Mean M1G/M1total was 27 (SD 15) % and was significantly lower in early compared to late neonatal life (22 versus 32%, p=0.0001).",Both postnatal and postmenstrual age contribute to the interindividual variability in tramadol glucuronidation in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17913403/),%,32,118944,DB00193,Tramadol
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],551,121331,DB00193,Tramadol
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],632,121332,DB00193,Tramadol
,28888220,maximum plasma concentration (Cmax ),"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[ng] / [ml],661,121333,DB00193,Tramadol
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],4796,121334,DB00193,Tramadol
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],4990,121335,DB00193,Tramadol
,28888220,area under the plasma concentration-time curve over the dosing interval at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),[h·ng] / [ml],5284,121336,DB00193,Tramadol
,28888220,time to Cmax at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),h,3.0,121337,DB00193,Tramadol
,28888220,time to Cmax at steady state,"Multiple-dose tramadol PK parameters for treatments 1, 2 and 4, respectively, were 551, 632 and 661 ng ml-1 [mean maximum plasma concentration (Cmax )]; 4796, 4990 and 5284 ng h ml-1 (area under the plasma concentration-time curve over the dosing interval at steady state); and 3.0, 2.0 and 2.0 h (median time to Cmax at steady state).",Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28888220/),h,2.0,121338,DB00193,Tramadol
,17904881,distribution half-life (t(1/2)(alpha)),"The results (means+/-SEM) were as follows: after IV drug administration, the distribution half-life (t(1/2)(alpha)) was 0.22+/-0.05 h, the elimination half-life (t(1/2)(beta)) 1.33+/-0.18 h, the total body clearance (Cl(T)) 1.94+/-0.18 L h kg(-1), the volume of distribution at steady state (Vd(ss)) 2.58+/-0.44 L kg(-1), and the area under the concentration vs. time curve (AUC(0-infinity)) 1.25+/-0.13 mg h L(-1).","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,0.22,121462,DB00193,Tramadol
,17904881,elimination half-life (t(1/2)(beta)),"The results (means+/-SEM) were as follows: after IV drug administration, the distribution half-life (t(1/2)(alpha)) was 0.22+/-0.05 h, the elimination half-life (t(1/2)(beta)) 1.33+/-0.18 h, the total body clearance (Cl(T)) 1.94+/-0.18 L h kg(-1), the volume of distribution at steady state (Vd(ss)) 2.58+/-0.44 L kg(-1), and the area under the concentration vs. time curve (AUC(0-infinity)) 1.25+/-0.13 mg h L(-1).","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,1.33,121463,DB00193,Tramadol
,17904881,total body clearance (Cl(T)),"The results (means+/-SEM) were as follows: after IV drug administration, the distribution half-life (t(1/2)(alpha)) was 0.22+/-0.05 h, the elimination half-life (t(1/2)(beta)) 1.33+/-0.18 h, the total body clearance (Cl(T)) 1.94+/-0.18 L h kg(-1), the volume of distribution at steady state (Vd(ss)) 2.58+/-0.44 L kg(-1), and the area under the concentration vs. time curve (AUC(0-infinity)) 1.25+/-0.13 mg h L(-1).","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[h·l] / [kg],1.94,121464,DB00193,Tramadol
,17904881,volume of distribution at steady state (Vd(ss)),"The results (means+/-SEM) were as follows: after IV drug administration, the distribution half-life (t(1/2)(alpha)) was 0.22+/-0.05 h, the elimination half-life (t(1/2)(beta)) 1.33+/-0.18 h, the total body clearance (Cl(T)) 1.94+/-0.18 L h kg(-1), the volume of distribution at steady state (Vd(ss)) 2.58+/-0.44 L kg(-1), and the area under the concentration vs. time curve (AUC(0-infinity)) 1.25+/-0.13 mg h L(-1).","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[l] / [kg],2.58,121465,DB00193,Tramadol
,17904881,area under the concentration vs. time curve (AUC(0-infinity)),"The results (means+/-SEM) were as follows: after IV drug administration, the distribution half-life (t(1/2)(alpha)) was 0.22+/-0.05 h, the elimination half-life (t(1/2)(beta)) 1.33+/-0.18 h, the total body clearance (Cl(T)) 1.94+/-0.18 L h kg(-1), the volume of distribution at steady state (Vd(ss)) 2.58+/-0.44 L kg(-1), and the area under the concentration vs. time curve (AUC(0-infinity)) 1.25+/-0.13 mg h L(-1).","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[h·mg] / [l],1.25,121466,DB00193,Tramadol
,17904881,maximal plasma tramadol concentration (C(max)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[μg] / [ml],0.44,121467,DB00193,Tramadol
,17904881,time (T(max)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,0.57,121468,DB00193,Tramadol
,17904881,absorption half-life (t(1/2 ka)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,0.17,121469,DB00193,Tramadol
,17904881,t(1/2)(beta)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,3.24,121470,DB00193,Tramadol
,17904881,AUC(0-infinity)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[h·mg] / [l],1.27,121471,DB00193,Tramadol
,17904881,Vd(area)),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),[l] / [kg],8.94,121472,DB00193,Tramadol
,17904881,systemic bioavailability (F),"Following IM administration, the maximal plasma tramadol concentration (C(max)) reached was 0.44+/-0.07 microg mL(-1) at time (T(max)) 0.57+/-0.11h; the absorption half-life (t(1/2 ka)) was 0.17+/-0.03 h, the (t(1/2)(beta)) was 3.24+/-0.55 h, the (AUC(0-infinity)) was 1.27+/-0.12 mg h L(-1), the (Vd(area)) was 8.94+/-1.41 L kg(-1), and the mean systemic bioavailability (F) was 101.62%.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),%,101.62,121473,DB00193,Tramadol
,17904881,urinary detection times,"The urinary detection times for tramadol and O-desmethyltramadol were 24 and 48 h, respectively.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,24,121474,DB00193,Tramadol
,17904881,urinary detection times,"The urinary detection times for tramadol and O-desmethyltramadol were 24 and 48 h, respectively.","The pharmacokinetics, metabolism and urinary detection time of tramadol in camels. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904881/),h,48,121475,DB00193,Tramadol
,27030842,volume of distribution,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·kg],5.10,121753,DB00193,Tramadol
,27030842,volume of distribution,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·kg],4.63,121754,DB00193,Tramadol
,27030842,volume of distribution,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·kg],4.02,121755,DB00193,Tramadol
,27030842,volume of distribution,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·kg],3.84,121756,DB00193,Tramadol
,27030842,clearance,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·h·kg],3.44,121757,DB00193,Tramadol
,27030842,clearance,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·h·kg],3.08,121758,DB00193,Tramadol
,27030842,clearance,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·h·kg],3.14,121759,DB00193,Tramadol
,27030842,clearance,"The average volume of distribution was 5.10, 4.63, 4.02 and 3.84 l/kg bwt and clearance 3.44, 3.08, 3.14 and 2.69 l/h/kg bwt when foals were aged 6–8, 13–15, 20–22 and 40–43 days, respectively.","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),[l] / [bwt·h·kg],2.69,121760,DB00193,Tramadol
,27030842,elimination half-life,"There was not a significant difference in the elimination half-life between age groups (1.52, 1.73, 1.13 and 1.51 for ages 6–8, 13–15, 20–22 and 40–43 days, respectively).","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),,1.52,121761,DB00193,Tramadol
,27030842,elimination half-life,"There was not a significant difference in the elimination half-life between age groups (1.52, 1.73, 1.13 and 1.51 for ages 6–8, 13–15, 20–22 and 40–43 days, respectively).","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),,1.73,121762,DB00193,Tramadol
,27030842,elimination half-life,"There was not a significant difference in the elimination half-life between age groups (1.52, 1.73, 1.13 and 1.51 for ages 6–8, 13–15, 20–22 and 40–43 days, respectively).","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),,1.13,121763,DB00193,Tramadol
,27030842,elimination half-life,"There was not a significant difference in the elimination half-life between age groups (1.52, 1.73, 1.13 and 1.51 for ages 6–8, 13–15, 20–22 and 40–43 days, respectively).","Effects of age on the pharmacokinetics of tramadol and its active metabolite, O-desmethyltramadol following intravenous administration to foals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030842/),,1.51,121764,DB00193,Tramadol
,18672959,half-life,Mean +/- SD half-life of tramadol after administration was 145.4 +/- 81.0 minutes; mean +/- SD maximum plasma concentration was 135.3 +/- 89.1 ng/mL.,Pharmacokinetics of orally administered tramadol in domestic rabbits (Oryctolagus cuniculus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672959/),min,145.4,121851,DB00193,Tramadol
,18672959,maximum plasma concentration,Mean +/- SD half-life of tramadol after administration was 145.4 +/- 81.0 minutes; mean +/- SD maximum plasma concentration was 135.3 +/- 89.1 ng/mL.,Pharmacokinetics of orally administered tramadol in domestic rabbits (Oryctolagus cuniculus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18672959/),[ng] / [ml],135.3,121852,DB00193,Tramadol
,25228122,Globule sizes,"Globule sizes of TME and TNE were 16.69 ± 3.21 and 136.3 ± 4.3 nm, respectively.",Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228122/),nm,16.69,124706,DB00193,Tramadol
,25228122,Globule sizes,"Globule sizes of TME and TNE were 16.69 ± 3.21 and 136.3 ± 4.3 nm, respectively.",Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25228122/),nm,136.3,124707,DB00193,Tramadol
,24692782,serum Cmax,"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),[ng] / [ml],1385.5,124856,DB00193,Tramadol
,24692782,Tmax,"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),h,0.33,124857,DB00193,Tramadol
,24692782,terminal elimination half-life (t1/2β),"The mean (SD) serum Cmax of tramadol was 1385.5 (390.8) ng/mL, Tmax was 0.33 (0.22) hour, and terminal elimination half-life (t1/2β) was 10.5 (2.3) hours.","Pharmacokinetics and postoperative analgesia of epidural tramadol: A prospective, pilot study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24692782/),h,10.5,124858,DB00193,Tramadol
,33935773,t1/2,"After a dose of 100 mg of tramadol, t1/2 of 4.8 (3.2-7.6) h was observed.","Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935773/),h,4.8,126300,DB00193,Tramadol
,33935773,area under the concentration-time curve at the first dose interval (AUC1-6),"The area under the concentration-time curve at the first dose interval (AUC1-6) of tramadol was 1,200 (917.9-1944.4) μg ×h ×L-1.","Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935773/),[h·μg] / [l],"1,200",126301,DB00193,Tramadol
,33935773,AUC1-6,"ODT AUC1-6 was 229.6 (137.7-326.2) μg ×h ×L-1 and 95.5 (49.1-204.3) μg ×h ×L-1 in EM and IM, respectively (p = 0.004).","Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935773/),[h·μg] / [l],229.6,126302,DB00193,Tramadol
,33935773,AUC1-6,"ODT AUC1-6 was 229.6 (137.7-326.2) μg ×h ×L-1 and 95.5 (49.1-204.3) μg ×h ×L-1 in EM and IM, respectively (p = 0.004).","Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33935773/),[h·μg] / [l],95.5,126303,DB00193,Tramadol
,20137767,time to reach peak tram,"Although the two products were determined to be bioequivalent with respect to C(max) and AUC, the time to reach peak tramadol concentrations was significantly earlier for Tramadol Contramid OAD (6 hours vs. 10 hours).",Comparative bioavailability of two once-daily tramadol HCl 200 mg extended-release products in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137767/),h,6,130262,DB00193,Tramadol
,20137767,time to reach peak tram,"Although the two products were determined to be bioequivalent with respect to C(max) and AUC, the time to reach peak tramadol concentrations was significantly earlier for Tramadol Contramid OAD (6 hours vs. 10 hours).",Comparative bioavailability of two once-daily tramadol HCl 200 mg extended-release products in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137767/),h,10,130263,DB00193,Tramadol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],9.4,130306,DB00193,Tramadol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],4.7,130307,DB00193,Tramadol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],531.8,130308,DB00193,Tramadol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],1304.4,130309,DB00193,Tramadol
,18204346,area under the curve,"Median (+)R,R-tramadol area under the curve was 786 and 587 mug.h.",Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204346/),h·μg,786,130419,DB00193,Tramadol
,18204346,area under the curve,"Median (+)R,R-tramadol area under the curve was 786 and 587 mug.h.",Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204346/),h·μg,587,130420,DB00193,Tramadol
,18204346,area under the curve,"L in EMs and UMs, and the corresponding median (+)R,R-O-desmethyltramadol area under the curve was 416 and 448 mug.h.L (P = 0.005, t test).",Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204346/),h·l·μg,416,130421,DB00193,Tramadol
,18204346,area under the curve,"L in EMs and UMs, and the corresponding median (+)R,R-O-desmethyltramadol area under the curve was 416 and 448 mug.h.L (P = 0.005, t test).",Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18204346/),h·l·μg,448,130422,DB00193,Tramadol
,21384434,AUC((+))/((-)) ratio,"The kinetic disposition of trans-T and M2 was enantioselective (AUC((+))/((-)) ratio=4.16 and 6.36, respectively).","Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21384434/),,4.16,131863,DB00193,Tramadol
,21384434,AUC((+))/((-)) ratio,"The kinetic disposition of trans-T and M2 was enantioselective (AUC((+))/((-)) ratio=4.16 and 6.36, respectively).","Simultaneous analysis of tramadol, O-desmethyltramadol, and N-desmethyltramadol enantiomers in rat plasma by high-performance liquid chromatography-tandem mass spectrometry: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21384434/),,6.36,131864,DB00193,Tramadol
,18796225,flow,"The analyte and internal standard tramadol are extracted from plasma by liquid-liquid extraction using diethyl ether-dichloromethane (60:40 v/v), and separated on a Zorbax extend C18 column using methanol-10mM ammonium acetate (60:40 v/v, pH 4.0) at a flow of 1.0 mL/min.",Determination of ranolazine in human plasma by liquid chromatographic-tandem mass spectrometric assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18796225/),[ml] / [min],1.0,132642,DB00193,Tramadol
,22465199,ch,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),min,5.5,132710,DB00193,Tramadol
,22465199,run time,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),min,5.5,132711,DB00193,Tramadol
,22465199,LOD,The method has a chromatographic run time of 5.5 min and is linear within the concentration range 0.01-5.00 ng/mL for plasma and 0.10-30.00 ng/mL for urine both with a LOD of 0.003 ng/mL.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),[ng] / [ml],0.003,132712,DB00193,Tramadol
more,22465199,recovery rates,The recovery rates of palonosetron and IS both for plasma and urine were more than 90%.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),%,90,132713,DB00193,Tramadol
,22465199,urine accumulated excretory rate,The mean urine accumulated excretory rate was 25.97 ± 12.87%.,Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22465199/),%,25.97,132714,DB00193,Tramadol
,15662507,lag time,"Following intravenous administration of tramadol, a lag time of about 4 h was observed until full blood-brain equilibration was achieved.",Tramadol concentrations in blood and in cerebrospinal fluid in a neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15662507/),h,4,133398,DB00193,Tramadol
,25170803,Cmax,"The Cmax values following buccal and nasal administration were 6 times and 20 times higher than that of oral administration, respectively, (6827.85 ± 7970.87 ng/ml, 22191.84 ± 5364.86 ng/ml, vs 1127.03 ± 778.34 ng/ml).",Bioavailability of tramadol hydrochloride after administration via different routes in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170803/),[ng] / [ml],6827.85,134778,DB00193,Tramadol
,25170803,Cmax,"The Cmax values following buccal and nasal administration were 6 times and 20 times higher than that of oral administration, respectively, (6827.85 ± 7970.87 ng/ml, 22191.84 ± 5364.86 ng/ml, vs 1127.03 ± 778.34 ng/ml).",Bioavailability of tramadol hydrochloride after administration via different routes in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170803/),[ng] / [ml],22191.84,134779,DB00193,Tramadol
,25170803,Cmax,"The Cmax values following buccal and nasal administration were 6 times and 20 times higher than that of oral administration, respectively, (6827.85 ± 7970.87 ng/ml, 22191.84 ± 5364.86 ng/ml, vs 1127.03 ± 778.34 ng/ml).",Bioavailability of tramadol hydrochloride after administration via different routes in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170803/),[ng] / [ml],1127.03,134780,DB00193,Tramadol
,25170803,relative bioavailabilities,"The relative bioavailabilities of the nasal- and buccal-administered drug when compared with the oral route were 504.8% and 183.4%, respectively, which is much higher than that of oral administration.",Bioavailability of tramadol hydrochloride after administration via different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170803/),%,504.8,134781,DB00193,Tramadol
,25170803,relative bioavailabilities,"The relative bioavailabilities of the nasal- and buccal-administered drug when compared with the oral route were 504.8% and 183.4%, respectively, which is much higher than that of oral administration.",Bioavailability of tramadol hydrochloride after administration via different routes in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170803/),%,183.4,134782,DB00193,Tramadol
,12779111,duration of,The mean duration of anesthesia was 27.9 +/- 10.1 minutes.,Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),min,27.9,136685,DB00193,Tramadol
,12779111,elimination half-life,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),h,3.6,136686,DB00193,Tramadol
,12779111,serum clearance,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),[ml] / [kg·min],5.6,136687,DB00193,Tramadol
,12779111,volume of distribution,"The elimination half-life was 3.6 +/- 1.1 hours, the serum clearance 5.6 +/- 2.7 mL/kg/min, and the volume of distribution 4.1 +/- 1.2 L/kg.",Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),[l] / [kg],4.1,136688,DB00193,Tramadol
,12779111,elimination half-life,The M1 elimination half-life was 5.8 +/- 1.7 hours.,Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years--a pilot study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779111/),h,5.8,136689,DB00193,Tramadol
,31115034,Cmax (maximum plasma concentration),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[mg] / [l],3.41,141678,DB00193,Tramadol
,31115034,AUC0-inf (area under the plasma concentration-time curve from time zero to infinity),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·mg] / [l],10.45,141679,DB00193,Tramadol
,31115034,tmax (time to first occurrence of Cmax,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.94,141680,DB00193,Tramadol
,31115034,Cl (clearance),"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [h·kg],0.199,141681,DB00193,Tramadol
,31115034,Vd/kg,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141682,DB00193,Tramadol
,31115034,volume of distribution per kilo,"The main PK parameters for ketoprofen were as follows: Cmax (maximum plasma concentration), 3.41 [2.32] mg/L; AUC0-inf (area under the plasma concentration-time curve from time zero to infinity), 10.45 [5.57] mg⋅h/L; tmax (time to first occurrence of Cmax), 1.94 [1.25] h; Cl (clearance), 0.199 [0.165] L/kg·h, and Vd/kg (volume of distribution per kilogram of body weight), 0.71 [0.58] L/kg.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[l] / [kg],0.71,141683,DB00193,Tramadol
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],226.4,141684,DB00193,Tramadol
,31115034,Cmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[ng] / [ml],55.6,141685,DB00193,Tramadol
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],1903.3,141686,DB00193,Tramadol
,31115034,AUC0-inf,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),[h·ng] / [ml],790.4,141687,DB00193,Tramadol
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,1.78,141688,DB00193,Tramadol
,31115034,tmax,"The main PK parameters for TRM and M1 were as follows: Cmax, 226.4 [80.5] and 55.6 [23] ng/mL; AUC0-inf, 1903.3 [874.8] and 790.4 [512.4] ng⋅h/mL; tmax, 1.78 [0.73] and 2.67 [1.19] h, respectively.",Ketoprofen and tramadol pharmacokinetics in patients with chronic pancreatitis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31115034/),h,2.67,141689,DB00193,Tramadol
,15058586,flow rate,The flow rate was 0.5 ml/min.,Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography. Application to a pharmacokinetic study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058586/),[ml] / [min],0.5,142585,DB00193,Tramadol
above,15058586,recoveries,Mean recoveries above of 95% for each enantiomer were obtained.,Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography. Application to a pharmacokinetic study in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058586/),%,95,142586,DB00193,Tramadol
,32513525,maximum concentration,"After IN administration, tramadol was rapidly absorbed into the systemic circulation, reaching its maximum concentration (range 74.74-200.29 ng mL-1) within 30-60 minutes, it then decreased rapidly and was detectable in plasma for up to 2 hours after treatment in all dogs.",Pharmacokinetics and analgesic efficacy of intranasal administration of tramadol in dogs after ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32513525/),[ng] / [ml],74.74-200.29,146664,DB00193,Tramadol
,18282749,flow rate,"Chromatography was performed on an AGP column containing alpha1-acid glycoprotein as chiral selector with a mobile phase of 30 mM diammonium hydrogen phosphate buffer-acetonitrile-triethylamine (98.9:1:0.1, v/v), adjusted to pH 7 by phosphoric acid, and a flow rate of 0.5 ml/min.",Enantioselective determination of tramadol and its main phase I metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282749/),[ml] / [min],0.5,146812,DB00193,Tramadol
>,18282749,recoveries,Mean recoveries of enantiomers from plasma samples were > 81% for all analytes.,Enantioselective determination of tramadol and its main phase I metabolites in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282749/),%,81,146813,DB00193,Tramadol
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],259,146999,DB00193,Tramadol
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],318,147000,DB00193,Tramadol
,34167827,Cmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],165,147001,DB00193,Tramadol
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],1930,147002,DB00193,Tramadol
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2348,147003,DB00193,Tramadol
,34167827,AUC0-T,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],1929,147004,DB00193,Tramadol
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,1.5,147005,DB00193,Tramadol
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,3.0,147006,DB00193,Tramadol
,34167827,Tmax,"For Treatment-1, -3, and -4, celecoxib PK parameters were 259, 318, and 165 ng/mL (Cmax), respectively; 1930, 2348, and 1929 ng • h/mL (AUC0-T); and 1.5, 3.0, and 2.5 hours (Tmax).",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.5,147007,DB00193,Tramadol
,34167827,Cmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],305/78,147008,DB00193,Tramadol
,34167827,Cmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[ng] / [ml],312/78,147009,DB00193,Tramadol
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2507/846,147010,DB00193,Tramadol
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2709/965,147011,DB00193,Tramadol
,34167827,AUC0-T,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),[h·ng] / [ml],2888/1010,147012,DB00193,Tramadol
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,3.0,147013,DB00193,Tramadol
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.0,147014,DB00193,Tramadol
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,1.9/,147015,DB00193,Tramadol
,34167827,Tmax,"Tramadol/O-desmethyl tramadol PK parameters for Treatment-1, -2, and -4 were 214/55, 305/78, and 312/78 ng/mL for Cmax; 2507/846, 2709/965, and 2888/1010 ng • h/mL for AUC0-T; and 3.0/4.0, 2.0/2.5, and 1.9/2.5 hours for Tmax.",Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34167827/),h,2.5,147016,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],82-587,147422,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],127-1280,147423,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],2.51-26.7,147424,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],4.88-34.3,147425,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],12.5-356,147426,DB00193,Tramadol
,24180699,maximum plasma concentrations (Cmax ),"Following tramadol at 5 and 10 mg/kg, respectively, maximum plasma concentrations (Cmax ) of tramadol ranged from 82-587 and 127-1280 ng/mL, nonconjugated M1 ranged from 2.51-26.7 and 4.88-34.3 ng/mL, and nonconjugated M2 from 12.5-356 and 35.4-486 ng/mL.",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],35.4-486,147427,DB00193,Tramadol
,24180699,minimum plasma concentrations (Cmin ),Corresponding minimum plasma concentrations (Cmin ) of tramadol at 12 h following each dose ranged from 0.8-24 and 3-117 ng/mL.,Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],0.8-24,147428,DB00193,Tramadol
,24180699,minimum plasma concentrations (Cmin ),Corresponding minimum plasma concentrations (Cmin ) of tramadol at 12 h following each dose ranged from 0.8-24 and 3-117 ng/mL.,Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),[ng] / [ml],3-117,147429,DB00193,Tramadol
,24180699,accumulation indexes,"Tramadol accumulated considerably over time, more markedly when given at 10 mg/kg than at 5 mg/kg (accumulation indexes of 3.51 and 1.73 respectively).",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),,3.51,147430,DB00193,Tramadol
,24180699,accumulation indexes,"Tramadol accumulated considerably over time, more markedly when given at 10 mg/kg than at 5 mg/kg (accumulation indexes of 3.51 and 1.73 respectively).",Pharmacokinetics and physiological effects of repeated oral administrations of tramadol in horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24180699/),,1.73,147431,DB00193,Tramadol
,27476294,Cmax (maximum blood drug level),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),[ng] / [ml],80.8,150139,DB00193,Tramadol
,27476294,Tmax (time required to attain maximum blood drug level),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),[ng] / [ml],119.6,150140,DB00193,Tramadol
,27476294,Tmax (time required to attain maximum blood drug level),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),h,11.4,150141,DB00193,Tramadol
,27476294,AUC (area under blood drug concentration curve),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),h,12.2,150142,DB00193,Tramadol
,27476294,AUC (area under blood drug concentration curve),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),[h·ng] / [ml],1430.5,150143,DB00193,Tramadol
,27476294,AUC (area under blood drug concentration curve),"The values of predicted pharmacokinetic parameters like Cmax (maximum blood drug level), Tmax (time required to attain maximum blood drug level), and AUC (area under blood drug concentration curve) ranged between 80.8 ± 3.2-119.6 ± 4.7 ng/mL, 11.4 ± 0.2-12.2 ± 0.2 h, and 1430.5 ± 209.5-1970.6 ± 287.4 ng.h/mL, respectively.",PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27476294/),[h·ng] / [ml],1970.6,150144,DB00193,Tramadol
,21492191,half-life,"Tramadol half-life, volume of distribution at steady-state and clearance after intravenous administration were 2.12 ± 0.37 h, 4.02 ± 1.16 L/kg and 1728.73 ± 152.82 mL/h/kg, respectively.",Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),h,2.12,150699,DB00193,Tramadol
,21492191,volume of distribution at steady-state,"Tramadol half-life, volume of distribution at steady-state and clearance after intravenous administration were 2.12 ± 0.37 h, 4.02 ± 1.16 L/kg and 1728.73 ± 152.82 mL/h/kg, respectively.",Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),[l] / [kg],4.02,150700,DB00193,Tramadol
,21492191,clearance,"Tramadol half-life, volume of distribution at steady-state and clearance after intravenous administration were 2.12 ± 0.37 h, 4.02 ± 1.16 L/kg and 1728.73 ± 152.82 mL/h/kg, respectively.",Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),[ml] / [h·kg],1728.73,150701,DB00193,Tramadol
,21492191,bioavailability,The bioavailability was 110 ± 21% and half-life 2.54 ± 0.31 h following intramuscular administration of tramadol.,Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),%,110,150702,DB00193,Tramadol
,21492191,half-life,The bioavailability was 110 ± 21% and half-life 2.54 ± 0.31 h following intramuscular administration of tramadol.,Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),h,2.54,150703,DB00193,Tramadol
,21492191,half-life,M1 had a half-life of 10.40 ± 2.90 h and 7.71 ± 0.54 h following intravenous and intramuscular administration of tramadol.,Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),h,10.40,150704,DB00193,Tramadol
,21492191,half-life,M1 had a half-life of 10.40 ± 2.90 h and 7.71 ± 0.54 h following intravenous and intramuscular administration of tramadol.,Pharmacokinetics of intravenous and intramuscular tramadol in llamas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492191/),h,7.71,150705,DB00193,Tramadol
,26056877,half-life,"After oral administration, the half-life of tramadol administered at 5 and 10 mg/kg was 20.35 and 22.67 hr, whereas the half-life of M1 was 10.23 and 11.26 hr, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),h,20.35,156246,DB00193,Tramadol
,26056877,half-life,"After oral administration, the half-life of tramadol administered at 5 and 10 mg/kg was 20.35 and 22.67 hr, whereas the half-life of M1 was 10.23 and 11.26 hr, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),h,22.67,156247,DB00193,Tramadol
,26056877,half-life,"After oral administration, the half-life of tramadol administered at 5 and 10 mg/kg was 20.35 and 22.67 hr, whereas the half-life of M1 was 10.23 and 11.26 hr, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),h,10.23,156248,DB00193,Tramadol
,26056877,half-life,"After oral administration, the half-life of tramadol administered at 5 and 10 mg/kg was 20.35 and 22.67 hr, whereas the half-life of M1 was 10.23 and 11.26 hr, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),h,11.26,156249,DB00193,Tramadol
,26056877,maximum concentration (Cmax),"The maximum concentration (Cmax) for tramadol after oral administration at 5 mg/kg and 10 mg/kg was 373 and 719 ng/ml, whereas that of M1 was 655 and 1,376 ng/ml, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),[ng] / [ml],373,156250,DB00193,Tramadol
,26056877,maximum concentration (Cmax),"The maximum concentration (Cmax) for tramadol after oral administration at 5 mg/kg and 10 mg/kg was 373 and 719 ng/ml, whereas that of M1 was 655 and 1,376 ng/ml, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),[ng] / [ml],719,156251,DB00193,Tramadol
,26056877,maximum concentration (Cmax),"The maximum concentration (Cmax) for tramadol after oral administration at 5 mg/kg and 10 mg/kg was 373 and 719 ng/ml, whereas that of M1 was 655 and 1,376 ng/ml, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),[ng] / [ml],655,156252,DB00193,Tramadol
,26056877,maximum concentration (Cmax),"The maximum concentration (Cmax) for tramadol after oral administration at 5 mg/kg and 10 mg/kg was 373 and 719 ng/ml, whereas that of M1 was 655 and 1,376 ng/ml, respectively.",PHARMACOKINETICS OF TRAMADOL AND O-DESMETHYLTRAMADOL IN LOGGERHEAD SEA TURTLES (CARETTA CARETTA). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056877/),[ng] / [ml],"1,376",156253,DB00193,Tramadol
,21883285,half-lives (t(1/2)),The mean half-lives (t(1/2)) i.v. were 0.85±0.463 and 0.520±0.256 h orally.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),h,0.85,161693,DB00193,Tramadol
,21883285,half-lives (t(1/2)),The mean half-lives (t(1/2)) i.v. were 0.85±0.463 and 0.520±0.256 h orally.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),h,0.520,161694,DB00193,Tramadol
,21883285,Cp(0),"The Cp(0) i.v. was 2467±540 ng/mL, and the C(max) was 1202±1319 ng/mL orally.",Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[ng] / [ml],2467,161695,DB00193,Tramadol
,21883285,C(max),"The Cp(0) i.v. was 2467±540 ng/mL, and the C(max) was 1202±1319 ng/mL orally.",Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[ng] / [ml],1202,161696,DB00193,Tramadol
,21883285,T(max),T(max) occurred at 0.111±0.068 h orally.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),h,0.111,161697,DB00193,Tramadol
,21883285,area under the curve (AUC(0-∞)),The area under the curve (AUC(0-∞)) i.v. was 895±189 and 373±217 ng*h/mL orally.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[h·ng] / [ml],895,161698,DB00193,Tramadol
,21883285,area under the curve (AUC(0-∞)),The area under the curve (AUC(0-∞)) i.v. was 895±189 and 373±217 ng*h/mL orally.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[h·ng] / [ml],373,161699,DB00193,Tramadol
,21883285,volume of distribution (V(d[area])),The volume of distribution (V(d[area])) i.v. was 5.50±2.66 L/kg.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[l] / [kg],5.50,161700,DB00193,Tramadol
,21883285,Total body clearance (Cl),Total body clearance (Cl) i.v. was 4.62±1.09 h; Cl/F for oral administration was 39.5±23 L/h/kg.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),h,4.62,161701,DB00193,Tramadol
,21883285,Cl/F,Total body clearance (Cl) i.v. was 4.62±1.09 h; Cl/F for oral administration was 39.5±23 L/h/kg.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),[l] / [h·kg],39.5,161702,DB00193,Tramadol
,21883285,mean residence time (MRT),The i.v. mean residence time (MRT) was 0.720±0.264.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),,0.720,161703,DB00193,Tramadol
,21883285,Oral adsorption (F),Oral adsorption (F) was low (5.9-19.1%) at almost three times the i.v. dosage with a large inter-subject variation.,Pharmacokinetics of tramadol and its major metabolites in alpacas following intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21883285/),%,5.9-19.1,161704,DB00193,Tramadol
,22173007,total,"The lower limits of quantitation were 0.2 and 0.5 ng/mL for analysis of total and unbound concentration of each tramadol enantiomer, respectively, and 0.1 and 0.25 ng/mL for total and unbound concentrations of M1 and M2 enantiomers, respectively.","Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173007/),[ng] / [ml],0.1,165476,DB00193,Tramadol
,22173007,unbound concentrations,"The lower limits of quantitation were 0.2 and 0.5 ng/mL for analysis of total and unbound concentration of each tramadol enantiomer, respectively, and 0.1 and 0.25 ng/mL for total and unbound concentrations of M1 and M2 enantiomers, respectively.","Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173007/),[ng] / [ml],0.1,165477,DB00193,Tramadol
,22173007,total,"The lower limits of quantitation were 0.2 and 0.5 ng/mL for analysis of total and unbound concentration of each tramadol enantiomer, respectively, and 0.1 and 0.25 ng/mL for total and unbound concentrations of M1 and M2 enantiomers, respectively.","Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173007/),[ng] / [ml],0.25,165478,DB00193,Tramadol
,22173007,unbound concentrations,"The lower limits of quantitation were 0.2 and 0.5 ng/mL for analysis of total and unbound concentration of each tramadol enantiomer, respectively, and 0.1 and 0.25 ng/mL for total and unbound concentrations of M1 and M2 enantiomers, respectively.","Enantioselective analysis of unbound tramadol, O-desmethyltramadol and N-desmethyltramadol in plasma by ultrafiltration and LC-MS/MS: application to clinical pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22173007/),[ng] / [ml],0.25,165479,DB00193,Tramadol
,21932392,recovery,Mean recovery of curdione from plasma was in the range 94.3-98.4%.,Determination of curdione in rabbit plasma by liquid chromatography mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21932392/),%,94.3-98.4,165864,DB00193,Tramadol
>,32486995,bioavailability,For drugs with a high bioavailability (> 70 %) only the impaired hepatic clearance has to be considered.,[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167613,DB00193,Tramadol
>,32486995,bioavailability,"Buprenorphine, fentanyl, hydromorphone, morphine, naloxone und tapentadol are drugs with a high first-pass effect, while the bioavailability of methadone, oxycodone and tramadol is > 70 %.",[Opioid therapy in patients with liver cirrhosis]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486995/),%,70,167614,DB00193,Tramadol
,15961977,recoveries,"Very low recoveries of (+)-M1 were found in poor metabolizers (0.53% [range, 0.1%-1.1%]) compared with extensive metabolizers (8.7% [range, 1.7%-23.2%]).",Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961977/),%,0.53,168389,DB00193,Tramadol
,15961977,recoveries,"Very low recoveries of (+)-M1 were found in poor metabolizers (0.53% [range, 0.1%-1.1%]) compared with extensive metabolizers (8.7% [range, 1.7%-23.2%]).",Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961977/),%,8.7,168390,DB00193,Tramadol
,15961977,visual antimode,The visual antimode was 2.0.,Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961977/),,2.0,168391,DB00193,Tramadol
,33719822,AUC,"Compared to the commercial tablet, the ATSC had a larger AUC value for tramadol (55.27 ± 11.06 vs. 92.62 ± 21.52 h·ng/ml).","Acetaminophen and tramadol hydrochloride-loaded soft gelatin capsule: preparation, dissolution and pharmacokinetics in beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719822/),[h·ng] / [ml],55.27,168570,DB00193,Tramadol
,33719822,AUC,"Compared to the commercial tablet, the ATSC had a larger AUC value for tramadol (55.27 ± 11.06 vs. 92.62 ± 21.52 h·ng/ml).","Acetaminophen and tramadol hydrochloride-loaded soft gelatin capsule: preparation, dissolution and pharmacokinetics in beagle dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33719822/),[h·ng] / [ml],92.62,168571,DB00193,Tramadol
,23249424,percentage drug release,CP9 (66% carbopol and compression load of 6 ton) with a percentage drug release of 89.03 after 12 hours were found to be most comparable to the marketed product in terms of similarity factor and most appropriately fits to zero-order kinetics.,"Design, development and in vitro-in vivo study of tramadol-paracetamol inlay tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23249424/),,89.03,174767,DB00193,Tramadol
,24905322,t(max),The comparison of the difference for the effervescent and conventional formulation gave an estimated decrease in t(max) of 0.5 h for paracetamol and 0.13 h for tramadol.,The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905322/),h,0.5,174987,DB00193,Tramadol
,24905322,t(max),The comparison of the difference for the effervescent and conventional formulation gave an estimated decrease in t(max) of 0.5 h for paracetamol and 0.13 h for tramadol.,The pharmacokinetics of the effervescent vs. conventional tramadol/paracetamol fixed-dose combination tablet in patients after total gastric resection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24905322/),h,0.13,174988,DB00193,Tramadol
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),h,3,176623,DB00193,Tramadol
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),,1,176624,DB00193,Tramadol
,21704237,"T(max,ss)","The T(max,ss) for tramadol was delayed until 3 hours after the ER treatment, compared with 1 hour after the IR treatment, whereas the T(max,ss) of acetaminophen was 30 minutes after each treatment.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),min,30,176625,DB00193,Tramadol
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],2789.0,176626,DB00193,Tramadol
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],2638.7,176627,DB00193,Tramadol
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],"42,635.0",176628,DB00193,Tramadol
,21704237,"AUC(0-12,ss)","The mean (SD) of AUC(0-12,ss) in the IR and ER formulations was 2789.0 (507.7) and 2638.7 (469.1) µg/h/L for tramadol and 42,635.0 (8711.2) and 40,394.3 (10,127.7) µg/h/L for acetaminophen, respectively.","Pharmacokinetics of extended-release versus conventional tramadol/acetaminophen fixed-dose combination tablets: an open-label, 2-treatment, multiple-dose, randomized-sequence crossover study in healthy korean male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21704237/),[μg] / [h·l],"40,394.3",176629,DB00193,Tramadol
,25417559,flow rate,"Chromatographic separation was performed by pumping the mobile phase containing acetonitrile, water and formic acid (89.2:11.7:0.1) for 2.0 min at a flow rate of 0.25 μL/min into a Hypersil-Gold C18 column, 20 × 2.0 mm (1.9 µm) from Thermoscientific, New York, USA.","Development and validation of a sensitive UHPLC-MS/MS method for the simultaneous analysis of tramadol, dextromethorphan chlorpheniramine and their major metabolites in human plasma in forensic context: application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25417559/),[μl] / [min],0.25,178279,DB00193,Tramadol
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],4.2,178518,DB00193,Tramadol
,27779354,V2,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],130,178519,DB00193,Tramadol
,27779354,Q,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·h·kg],6.02,178520,DB00193,Tramadol
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],2.03,178521,DB00193,Tramadol
,21281202,maximum plasma concentrations,"The mean maximum plasma concentrations of tramadol, O-desmethyltramadol, N-desmethyltramadol, and N,O-didesmethyltramadol were 215.7, 5.7, 379.1, and 2372 ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[ng] / [ml],215.7,180487,DB00193,Tramadol
,21281202,maximum plasma concentrations,"The mean maximum plasma concentrations of tramadol, O-desmethyltramadol, N-desmethyltramadol, and N,O-didesmethyltramadol were 215.7, 5.7, 379.1, and 2372 ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[ng] / [ml],5.7,180488,DB00193,Tramadol
,21281202,maximum plasma concentrations,"The mean maximum plasma concentrations of tramadol, O-desmethyltramadol, N-desmethyltramadol, and N,O-didesmethyltramadol were 215.7, 5.7, 379.1, and 2372 ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[ng] / [ml],379.1,180489,DB00193,Tramadol
,21281202,maximum plasma concentrations,"The mean maximum plasma concentrations of tramadol, O-desmethyltramadol, N-desmethyltramadol, and N,O-didesmethyltramadol were 215.7, 5.7, 379.1, and 2372 ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[ng] / [ml],2372,180490,DB00193,Tramadol
,21281202,area-under-the-curve,"The mean area-under-the-curve values for the compounds were 592, 16, 1,536, and 1,013 h·ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[h·ng] / [ml],592,180491,DB00193,Tramadol
,21281202,area-under-the-curve,"The mean area-under-the-curve values for the compounds were 592, 16, 1,536, and 1,013 h·ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[h·ng] / [ml],16,180492,DB00193,Tramadol
,21281202,area-under-the-curve,"The mean area-under-the-curve values for the compounds were 592, 16, 1,536, and 1,013 h·ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[h·ng] / [ml],"1,536",180493,DB00193,Tramadol
,21281202,area-under-the-curve,"The mean area-under-the-curve values for the compounds were 592, 16, 1,536, and 1,013 h·ng/mL, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),[h·ng] / [ml],"1,013",180494,DB00193,Tramadol
,21281202,terminal half-lives,"The terminal half-lives of the compounds were 1.1, 1.4, 2.3, and 3.6 hours, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),h,1.1,180495,DB00193,Tramadol
,21281202,terminal half-lives,"The terminal half-lives of the compounds were 1.1, 1.4, 2.3, and 3.6 hours, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),h,1.4,180496,DB00193,Tramadol
,21281202,terminal half-lives,"The terminal half-lives of the compounds were 1.1, 1.4, 2.3, and 3.6 hours, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),h,2.3,180497,DB00193,Tramadol
,21281202,terminal half-lives,"The terminal half-lives of the compounds were 1.1, 1.4, 2.3, and 3.6 hours, respectively.",Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21281202/),h,3.6,180498,DB00193,Tramadol
,19395215,C(max),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),[ng] / [ml],1.19,181537,DB00193,Tramadol
,19395215,T(max),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),h,0.77,181538,DB00193,Tramadol
,19395215,AUC(0-t),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),[h·ng] / [ml],3.42,181539,DB00193,Tramadol
,19395215,t(1/2),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),h,2.89,181540,DB00193,Tramadol
,15908287,recoveries,"The method was linear for tramadol (3-768 ng/ml) and ODT (1.5-384 ng/ml) with mean recoveries of 87.2% and 89.8%, respectively.",Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908287/),%,87.2,182040,DB00193,Tramadol
,15908287,recoveries,"The method was linear for tramadol (3-768 ng/ml) and ODT (1.5-384 ng/ml) with mean recoveries of 87.2% and 89.8%, respectively.",Improved HPLC method for the simultaneous determination of tramadol and O-desmethyltramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15908287/),%,89.8,182041,DB00193,Tramadol
more,28455212,elimination half-life,Plasma concentrations of tramadol rapidly decreased in the first 2 hours for both doses with an elimination half-life of more than 40 minutes.,Cardiovascular effects and intraoperative pharmacokinetics of tramadol in sheep undergoing spinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28455212/),min,40,183661,DB00193,Tramadol
,2278370,lock-out time,"Group 1 (G1, PCA, n = 10): loading dose 3 mg/kg T, demand dose 30 mg T, lock-out time 5 min, concurrent infusion 5 mg/h T; group 2 (G2, CI, n = 10): loading dose 3 mg/kg T, continuous infusion 0.35 mg/kg per h T.",[Tramadol in postoperative pain therapy. Patient-controlled analgesia versus continuous infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278370/),min,5,189596,DB00193,Tramadol
,2278370,plasma T levels,"Mean plasma T levels were 994 +/- 440 ng/ml and 1170 +/- 357 ng/ml (G1 and G2, respectively).",[Tramadol in postoperative pain therapy. Patient-controlled analgesia versus continuous infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278370/),[ng] / [ml],994,189597,DB00193,Tramadol
,2278370,plasma T levels,"Mean plasma T levels were 994 +/- 440 ng/ml and 1170 +/- 357 ng/ml (G1 and G2, respectively).",[Tramadol in postoperative pain therapy. Patient-controlled analgesia versus continuous infusion]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278370/),[ng] / [ml],1170,189598,DB00193,Tramadol
,9190324,half-life,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,5 to 7,190044,DB00193,Tramadol
,9190324,time to peak plasma concentration,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),h,3.1,190045,DB00193,Tramadol
,9190324,plasma protein binding,"From a pharmacokinetic standpoint, tramadol offers high bioavailability, with similar patterns after oral or parenteral administration (half-life 5 to 7 hours, time to peak plasma concentration 3.1 hours, and approximately 20% plasma protein binding).",[Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine]. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190324/),%,20,190046,DB00193,Tramadol
,10080652,recovery,Plasma samples were extracted with ethyl acetate in a one-step liquid-liquid extraction (recovery 88.5+/-2.1%).,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),%,88.5,191919,DB00193,Tramadol
,10080652,A,Accuracy of the assay in the concentration range examined was from 1.3 to 11.9% for the intra-day run and from 1.4 to 8.1% for the inter-day run.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),%,1.3 to 11.9,191920,DB00193,Tramadol
,10080652,limit of detection,A limit of detection was 9 ng/ml at a signal-to-noise ratio of 3.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),[ng] / [ml],9,191921,DB00193,Tramadol
,10080652,signal-to-noise ratio,A limit of detection was 9 ng/ml at a signal-to-noise ratio of 3.,High-performance liquid chromatographic method for determination of tramadol in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080652/),,3,191922,DB00193,Tramadol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00193,Tramadol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00193,Tramadol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00193,Tramadol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00193,Tramadol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00193,Tramadol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00193,Tramadol
,15664351,recovery,The recovery of tramadol from plasma averaged 90.40%.,Investigation of the pharmacokinetics and determination of tramadol in rabbit plasma by a high-performance liquid chromatography-diode array detector method using liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664351/),%,90.40,193251,DB00193,Tramadol
,15664351,Maximum plasma concentration (C(max)),"Maximum plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC) for tramadol were 14.3 microg mL(-1) and 42.2 microg h mL(-1), respectively.",Investigation of the pharmacokinetics and determination of tramadol in rabbit plasma by a high-performance liquid chromatography-diode array detector method using liquid-liquid extraction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664351/),[μg] / [ml],14.3,193252,DB00193,Tramadol
,15664351,area under the plasma concentration-time curve (AUC),"Maximum plasma concentration (C(max)) and area under the plasma concentration-time curve (AUC) for tramadol were 14.3 microg mL(-1) and 42.2 microg h mL(-1), respectively.",Investigation of the pharmacokinetics and determination of tramadol in rabbit plasma by a high-performance liquid chromatography-diode array detector method using liquid-liquid extraction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664351/),[h·μg] / [ml],42.2,193253,DB00193,Tramadol
,31743475,F (fraction absorbed),"After oral administration (20 mg/kg) of SK1326, the F (fraction absorbed) value was ~77.1%.",Pharmacokinetic studies of a novel tubulin inhibitor SK1326 in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31743475/),%,77.1,194060,DB00193,Tramadol
,20399588,flow rate,"Sarpogrelate and tramadol (internal standard, I.S.) were separated on a Venusil MP-C(18) column within 1.7 min, using acetonitrile:ammonium acetate (10 mM, pH 6.8) (55:45, v/v) as mobile phase at a flow rate of 1.2 mL/min with an approximately 1:1 split entering the mass spectrometer.",Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399588/),[ml] / [min],1.2,198115,DB00193,Tramadol
,34256890,F (Fraction absorbed),"After p.o. administration (10 mg/kg) of SK7324, F (Fraction absorbed) value was approximately 87.1%.","Determination of SK7324, a new class of hepatitis C virus inhibitor, in rat plasma by UPLC-MS/MS and its application to the pharmacokinetic study of SK7324. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256890/),%,87.1,198530,DB00193,Tramadol
,10719611,absolute bioavailability (F),"The extent of the absolute bioavailability (F) of tramadol in the drops, based on AUC data, was 70.6 (1.13)% with a 90% confidence interval of 65.9-75.6% (ANOVAlog).",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),%,70.6,198629,DB00193,Tramadol
,10719611,tmax,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,1.2,198630,DB00193,Tramadol
,10719611,Cmax,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),[ng] / [ml],136,198631,DB00193,Tramadol
,10719611,ka,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,0.23,198632,DB00193,Tramadol
,10719611,lag time t0,"The p.o. serum concentration peaks were reached after tmax = 1.2 (0.74, 1.5) h and amounted to Cmax = 136 (1.33) ng/ml, the half-life of absorption was t1/2,ka = 0.23 (1.89) h and the lag time t0 = 0.23 (0.20, 0.49) h.",Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10719611/),h,0.23,198633,DB00193,Tramadol
,23242004,Bioavailability,Bioavailability of oral tramadol was reduced by rifampicin from 66 to 49 % (P = 0.002).,Rifampicin markedly decreases the exposure to oral and intravenous tramadol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23242004/),%,66 to 49,198780,DB00193,Tramadol
,12590030,relative systemic availabilities,"The mean relative systemic availabilities (90% confidence intervals) for the once-daily tablets 150 mg and the once-daily tablets 200 mg versus the normal release capsules were 89.6 (83.3-95.8)% and 90.5 (84.6-96.8)%, respectively.","A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12590030/),%,89.6,199254,DB00193,Tramadol
,12590030,relative systemic availabilities,"The mean relative systemic availabilities (90% confidence intervals) for the once-daily tablets 150 mg and the once-daily tablets 200 mg versus the normal release capsules were 89.6 (83.3-95.8)% and 90.5 (84.6-96.8)%, respectively.","A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12590030/),%,90.5,199255,DB00193,Tramadol
,17044126,run time,"Separation by reversed-phase high-performance liquid chromatography using methanol/10 mM ammonium acetate (70: 30, v/v) as mobile phase was complete in a run time of 2.4 min.",Liquid chromatographic/tandem mass spectrometric method for the quantitation of tranilast in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044126/),min,2.4,202463,DB00193,Tramadol
,14998423,Cmax,"Thus, the mean (+/- sd) Cmax of tramadol were 646 +/- 192 and 300 +/- 94 ng ml-1 for Topalgic 4 x 50mg and Tramadol LP 200 mg, respectively (95% confidence interval on the difference expressed as a percentage 42-51).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ng] / [ml],646,204599,DB00193,Tramadol
,14998423,Cmax,"Thus, the mean (+/- sd) Cmax of tramadol were 646 +/- 192 and 300 +/- 94 ng ml-1 for Topalgic 4 x 50mg and Tramadol LP 200 mg, respectively (95% confidence interval on the difference expressed as a percentage 42-51).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ng] / [ml],300,204600,DB00193,Tramadol
,14998423,AUC infinity,"Thus, the mean AUC infinity of (+/-)tramadol obtained after multiple dosing were 4611 +/- 1944 and 5105 +/- 2101 ngh ml-1 after Topalgic 4 x 50mg and Tramadol LP 200 mg, respectively (95%CI 102-123%).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ngh] / [ml],4611,204601,DB00193,Tramadol
,14998423,AUC infinity,"Thus, the mean AUC infinity of (+/-)tramadol obtained after multiple dosing were 4611 +/- 1944 and 5105 +/- 2101 ngh ml-1 after Topalgic 4 x 50mg and Tramadol LP 200 mg, respectively (95%CI 102-123%).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ngh] / [ml],5105,204602,DB00193,Tramadol
,14998423,AUC infinity,"Thus, the mean AUC infinity of (+/-) tramadol were 5444 +/- 1637 and 5169 +/- 1580 ngh ml-1 after Tramadol LP 200 mg given in the fasting and fed states, respectively (95%CI = 88-103%).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ngh] / [ml],5444,204603,DB00193,Tramadol
,14998423,AUC infinity,"Thus, the mean AUC infinity of (+/-) tramadol were 5444 +/- 1637 and 5169 +/- 1580 ngh ml-1 after Tramadol LP 200 mg given in the fasting and fed states, respectively (95%CI = 88-103%).",Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14998423/),[ngh] / [ml],5169,204604,DB00193,Tramadol
,20223494,half-life,"Tramadol was administered orally to six horses and its half-life, T(max) and C(max) in plasma were 10.1, 0.59 h, and 132.7 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),h,10.1,208286,DB00193,Tramadol
,20223494,T(max),"Tramadol was administered orally to six horses and its half-life, T(max) and C(max) in plasma were 10.1, 0.59 h, and 132.7 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),h,0.59,208287,DB00193,Tramadol
,20223494,C(max),"Tramadol was administered orally to six horses and its half-life, T(max) and C(max) in plasma were 10.1, 0.59 h, and 132.7 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),[ng] / [ml],132.7,208288,DB00193,Tramadol
,20223494,half-life,"The half-life, T(max) and C(max) for M1 in plasma were 4.0, 0.59 h, and 28.0 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),h,4.0,208289,DB00193,Tramadol
,20223494,T(max),"The half-life, T(max) and C(max) for M1 in plasma were 4.0, 0.59 h, and 28.0 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),h,0.59,208290,DB00193,Tramadol
,20223494,C(max),"The half-life, T(max) and C(max) for M1 in plasma were 4.0, 0.59 h, and 28.0 ng/mL, respectively.",Determination of oral tramadol pharmacokinetics in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20223494/),[ng] / [ml],28.0,208291,DB00193,Tramadol
,17532685,area under the curve (AUC(infinity),The two formulations were equivalent in the area under the curve (AUC(infinity): 2411 vs 2527 mug .,Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),μg,2411,210320,DB00193,Tramadol
,17532685,area under the curve (AUC(infinity),The two formulations were equivalent in the area under the curve (AUC(infinity): 2411 vs 2527 mug .,Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),μg,2527,210321,DB00193,Tramadol
,17532685,C(max),"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),[μg] / [l],148.6,210322,DB00193,Tramadol
,17532685,C(max),"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),[μg] / [l],183.2,210323,DB00193,Tramadol
,17532685,time to reach C(max),"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),h,5.9,210324,DB00193,Tramadol
,17532685,time to reach C(max),"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),h,4.9,210325,DB00193,Tramadol
,17532685,half-value duration,"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),h,13.4,210326,DB00193,Tramadol
,17532685,half-value duration,"However, capsules led to a lower C(max) (148.6 vs 183.2 mug/L), to a later time to reach C(max) (5.9 vs 4.9 hours), and to a longer half-value duration (13.4 vs 10.4 hours).",Tramadol SR Formulations : Pharmacokinetic Comparison of a Multiple-Units Dose (Capsule) versus a Single-Unit Dose (Tablet). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17532685/),h,10.4,210327,DB00193,Tramadol
,23061925,Cmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),[ng] / [ml],43.1,212333,DB00193,Tramadol
,23061925,Tmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),[ng] / [ml],90.7,212334,DB00193,Tramadol
,23061925,Tmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),[ng] / [ml],218,212335,DB00193,Tramadol
,23061925,Tmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,0.750,212336,DB00193,Tramadol
,23061925,Tmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,2.0,212337,DB00193,Tramadol
,23061925,Tmax,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,2.14,212338,DB00193,Tramadol
,23061925,t1/2λ,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,1.5,212339,DB00193,Tramadol
,23061925,t1/2λ,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,2.14,212340,DB00193,Tramadol
,23061925,t1/2λ,"For the 3, 6, and 9 mg/kg dose groups, Cmax , Tmax, and the t1/2λ were 43.1, 90.7, and 218 ng/mL, 0.750, 2.0, and 1.5 h and 2.14, 2.25, and 2.39 h, respectively.",Pharmacokinetics and pharmacodynamics of tramadol in horses following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061925/),h,2.25,212341,DB00193,Tramadol
,18718117,plasma absolute bioavailability,"The plasma absolute bioavailability values of tramadol after intranasal and oral administration were 73.8% and 32.4%, respectively, in conscious rats.",Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718117/),%,73.8,212689,DB00193,Tramadol
,18718117,plasma absolute bioavailability,"The plasma absolute bioavailability values of tramadol after intranasal and oral administration were 73.8% and 32.4%, respectively, in conscious rats.",Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718117/),%,32.4,212690,DB00193,Tramadol
,18718117,absolute bioavailability,"The absolute bioavailability values in plasma and CSF after intranasal administration were 66.7% and 87.3%, respectively.",Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718117/),%,66.7,212691,DB00193,Tramadol
,18718117,absolute bioavailability,"The absolute bioavailability values in plasma and CSF after intranasal administration were 66.7% and 87.3%, respectively.",Pharmacokinetics of tramadol in rat plasma and cerebrospinal fluid after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18718117/),%,87.3,212692,DB00193,Tramadol
,33892588,peak concentration (Cmax),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),[ng] / [ml],143,216544,DB00193,Tramadol
,33892588,half-life (T 1/2),"Results revealed detectable plasma concentrations in only 2 of 7 birds (29%), and the bird with the highest plasma levels had a peak concentration (Cmax) of 143 ng/mL and a half-life (T 1/2) of 24.8 minutes.",Pilot Study of a Single Dose of Orally Administered Tapentadol Suspension in Hispaniolan Amazon Parrots (Amazona ventralis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892588/),min,24.8,216545,DB00193,Tramadol
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,95.95,216674,DB00193,Tramadol
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,97.87,216675,DB00193,Tramadol
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,97.70,216676,DB00193,Tramadol
,10224654,recoveries,"Mean recoveries of 95.95 and 97.87% for (+)R,R- and (-)S,S-tramadol and 97.70 and 98.79% for (+)R,R- and (-)S,S-O-demethyltramadol with CVs < 2.15% were obtained.",Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10224654/),%,98.79,216677,DB00193,Tramadol
,18348341,half-life,"The tramadol concentration decreased from 297.8 to 159.6 ng/ml, with a mean half-life of 232.4 min and a hepatic clearance of 0.73 ml/min.",A disposition kinetic study of tramadol in rat perfused liver. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348341/),min,232.4,216824,DB00193,Tramadol
,18348341,hepatic clearance,"The tramadol concentration decreased from 297.8 to 159.6 ng/ml, with a mean half-life of 232.4 min and a hepatic clearance of 0.73 ml/min.",A disposition kinetic study of tramadol in rat perfused liver. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18348341/),[ml] / [min],0.73,216825,DB00193,Tramadol
,21728858,Maximum mean,"Maximum mean ± SEM serum concentrations after IV administration for tramadol, ODT, and NDT were 5,027 ± 638 ng/mL, 0 ng/mL, and 73.7 ± 12.9 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],"5,027",220705,DB00193,Tramadol
,21728858,serum concentrations,"Maximum mean ± SEM serum concentrations after IV administration for tramadol, ODT, and NDT were 5,027 ± 638 ng/mL, 0 ng/mL, and 73.7 ± 12.9 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],"5,027",220706,DB00193,Tramadol
,21728858,serum concentrations,"Maximum mean ± SEM serum concentrations after IV administration for tramadol, ODT, and NDT were 5,027 ± 638 ng/mL, 0 ng/mL, and 73.7 ± 12.9 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],0,220707,DB00193,Tramadol
,21728858,serum concentrations,"Maximum mean ± SEM serum concentrations after IV administration for tramadol, ODT, and NDT were 5,027 ± 638 ng/mL, 0 ng/mL, and 73.7 ± 12.9 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],73.7,220708,DB00193,Tramadol
,21728858,half-life,"For tramadol, half-life, volume of distribution, area under the curve, and total body clearance after IV administration were 2.55 ± 0.88 hours, 4.02 ± 1.35 L/kg, 2,701 ± 275 h x ng/mL, and 30.1 ± 2.56 mL/min/kg, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),h,2.55,220709,DB00193,Tramadol
,21728858,area under the curve,"For tramadol, half-life, volume of distribution, area under the curve, and total body clearance after IV administration were 2.55 ± 0.88 hours, 4.02 ± 1.35 L/kg, 2,701 ± 275 h x ng/mL, and 30.1 ± 2.56 mL/min/kg, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[l] / [kg],4.02,220710,DB00193,Tramadol
,21728858,total body clearance,"For tramadol, half-life, volume of distribution, area under the curve, and total body clearance after IV administration were 2.55 ± 0.88 hours, 4.02 ± 1.35 L/kg, 2,701 ± 275 h x ng/mL, and 30.1 ± 2.56 mL/min/kg, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ml] / [kg·min],30.1,220711,DB00193,Tramadol
,21728858,Maximal serum concentrations,"Maximal serum concentrations after oral administration for tramadol, ODT, and NDT were 238 ± 41.3 ng/mL, 86.8 ± 17.8 ng/mL, and 159 ± 20.4 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],238,220712,DB00193,Tramadol
,21728858,Maximal serum concentrations,"Maximal serum concentrations after oral administration for tramadol, ODT, and NDT were 238 ± 41.3 ng/mL, 86.8 ± 17.8 ng/mL, and 159 ± 20.4 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],86.8,220713,DB00193,Tramadol
,21728858,Maximal serum concentrations,"Maximal serum concentrations after oral administration for tramadol, ODT, and NDT were 238 ± 41.3 ng/mL, 86.8 ± 17.8 ng/mL, and 159 ± 20.4 ng/mL, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],159,220714,DB00193,Tramadol
,21728858,half-life,"After oral administration, half-life for tramadol, ODT, and NDT was 2.14 ± 0.50 hours, 1.01 ± 0.15 hours, and 2.62 ± 0.49 hours, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),h,2.14,220715,DB00193,Tramadol
,21728858,half-life,"After oral administration, half-life for tramadol, ODT, and NDT was 2.14 ± 0.50 hours, 1.01 ± 0.15 hours, and 2.62 ± 0.49 hours, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),h,1.01,220716,DB00193,Tramadol
,21728858,half-life,"After oral administration, half-life for tramadol, ODT, and NDT was 2.14 ± 0.50 hours, 1.01 ± 0.15 hours, and 2.62 ± 0.49 hours, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),h,2.62,220717,DB00193,Tramadol
,21728858,Bioavailability,Bioavailability of tramadol was 9.50 ± 1.28%.,Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),%,9.50,220718,DB00193,Tramadol
>,21728858,concentrations,"After oral administration, concentrations achieved minimum therapeutic ranges for humans for tramadol (> 100 ng/mL) and ODT (> 10 ng/mL) for 2.2 ± 0.46 hours and 2.04 ± 0.30 hours, respectively.",Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21728858/),[ng] / [ml],100,220719,DB00193,Tramadol
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.97,221407,DB00193,Tramadol
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.98,221408,DB00193,Tramadol
,15482390,Vd,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),l,167.6,221838,DB00193,Tramadol
,15482390,Vd,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),l,161.48,221839,DB00193,Tramadol
,15482390,kel,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),1/[h],0.1241,221840,DB00193,Tramadol
,15482390,kel,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),1/[h],0.1138,221841,DB00193,Tramadol
,15482390,ClT,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),[l] / [h],19.57,221842,DB00193,Tramadol
,15482390,ClT,"The one-compartmental model pharmacokinetic parameters--volume of distribution (Vd), elimination rate constant (kel) and the total clearance rates (ClT)--found were: mean Vd = 167.6 +/- 63.84 L; median Vd = 161.48 L; mean kel = 0.1241 +/- 0.056 h(-1); median kel = 0.1138 h(-1); ClT = 19.57 +/- 9.51 L/h; median ClT =18.12 L/h.",Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15482390/),[l] / [h],18.12,221843,DB00193,Tramadol
,12606644,maximum degree of inhibition,"Inhibition of both (+)-M1 formation clearance (CL(M10)) and CL(ME0) were modeled by an inhibitory E(MAX) model, and the estimates (relative standard error) of the maximum degree of inhibition (E(MAX)) and IC(50), plasma concentration of Q eliciting half of E(MAX) for CL(M10) and CL(ME0), were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml, respectively.",Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12606644/),[ng] / [ml],0.94,222715,DB00193,Tramadol
,12606644,IC(50),"Inhibition of both (+)-M1 formation clearance (CL(M10)) and CL(ME0) were modeled by an inhibitory E(MAX) model, and the estimates (relative standard error) of the maximum degree of inhibition (E(MAX)) and IC(50), plasma concentration of Q eliciting half of E(MAX) for CL(M10) and CL(ME0), were 0.94 (0.04), 97 (0.51) ng/ml, and 48 (0.42) ng/ml, respectively.",Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12606644/),[ng] / [ml],97,222716,DB00193,Tramadol
,18303070,clearance,"Tramadol clearance at term age was 17.1 litre h(-1) (70 kg)(-1) (CV, 37.2%).",Covariates of tramadol disposition in the first months of life. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303070/),[l] / [h],17.1,222738,DB00193,Tramadol
,18303070,formation clearance (CL2M1,"M1 formation clearance (CL2M1, i.e. the contribution of M1 synthesis to M clearance) was 4.11 litre h(-1) (70 kg)(-1) (CV, 110.9%) at term age.",Covariates of tramadol disposition in the first months of life. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18303070/),[70·l] / [h],4.11,222739,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224505,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224506,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,195.1,224507,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,138.3,224508,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,275.2,224509,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,230.3,224510,DB00193,Tramadol
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,264.2,224511,DB00193,Tramadol
,21394525,relative infant doses,"The estimated relative infant doses in extensive and poor metabolizers, respectively, were 2.16 ± 0.57 and 2.60 ± 0.57% for tramadol, and 0.93 ± .20 and 0.47 ± 0.10% for ODT.",Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394525/),%,2.16,224875,DB00193,Tramadol
,21394525,relative infant doses,"The estimated relative infant doses in extensive and poor metabolizers, respectively, were 2.16 ± 0.57 and 2.60 ± 0.57% for tramadol, and 0.93 ± .20 and 0.47 ± 0.10% for ODT.",Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394525/),%,2.60,224876,DB00193,Tramadol
,21394525,relative infant doses,"The estimated relative infant doses in extensive and poor metabolizers, respectively, were 2.16 ± 0.57 and 2.60 ± 0.57% for tramadol, and 0.93 ± .20 and 0.47 ± 0.10% for ODT.",Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394525/),%,0.93,224877,DB00193,Tramadol
,21394525,relative infant doses,"The estimated relative infant doses in extensive and poor metabolizers, respectively, were 2.16 ± 0.57 and 2.60 ± 0.57% for tramadol, and 0.93 ± .20 and 0.47 ± 0.10% for ODT.",Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21394525/),%,0.47,224878,DB00193,Tramadol
,14650359,bioavailability,Following oral administration the bioavailability of tramadol is high (70-90%) and with new slow release preparations twice daily administration enables effective pain control.,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,70-90,227851,DB00193,Tramadol
,14650359,plasma protein binding,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),%,20,227852,DB00193,Tramadol
,14650359,apparent volume of distribution,Tramadol is characterised by low plasma protein binding (20%) and quite extensive tissue distribution (apparent volume of distribution about 3 l/kg).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[l] / [kg],3,227853,DB00193,Tramadol
,14650359,Elimination half-lives,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),h,4.5 and 9.5,227854,DB00193,Tramadol
,14650359,total plasma clearance,Elimination half-lives of the active agents range between 4.5 and 9.5 h and total plasma clearance of tramadol is moderately high (600 ml/min).,Tramadol--the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14650359/),[ml] / [min],600,227855,DB00193,Tramadol
,24914400,maximum venous concentration,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),[mcg] / [ml],0.44,228922,DB00193,Tramadol
,24914400,maximum venous concentration,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),[mcg] / [ml],0.47,228923,DB00193,Tramadol
,24914400,area under the plasma concentration-time curve,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),[mcg] / [min·ml],177,228924,DB00193,Tramadol
,24914400,area under the plasma concentration-time curve,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),[mcg] / [min·ml],175,228925,DB00193,Tramadol
,24914400,time to maximum venous concentration,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),min,23.3,228926,DB00193,Tramadol
,24914400,time to maximum venous concentration,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),min,20.6,228927,DB00193,Tramadol
,24914400,mean residence time,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),min,463,228928,DB00193,Tramadol
,24914400,mean residence time,There were no statistically significant differences between the two groups in the following parameters (mean ± SD): maximum venous concentration 0.44 ± 0.18 (patients) vs. 0.47 ± 0.13 (healthy volunteers) mcg/ml (p = 0.67); area under the plasma concentration-time curve 177 ± 109 (patients) vs. 175 ± 75 (healthy volunteers) mcg/ml*min (p = 0.96); time to maximum venous concentration 23.3 ± 2 (patients) vs. 20.6 ± 18.8 (healthy volunteers) minutes (p = 0.73) and mean residence time 463 ± 233 (patients) vs. 466 ± 224 (healthy volunteers) minutes (p = 0.97).,Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24914400/),min,466,228929,DB00193,Tramadol
,25211185,concentration,"Mean tramadol concentration was 14.87 ± 11.14 μg/mL at 0.08 h, and 0.05 ± 0.06 μg/mL at 10 h.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],14.87,228970,DB00193,Tramadol
,25211185,concentration,"Mean tramadol concentration was 14.87 ± 11.14 μg/mL at 0.08 h, and 0.05 ± 0.06 μg/mL at 10 h.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.05,228971,DB00193,Tramadol
,25211185,maximum concentration (Cmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.05,228972,DB00193,Tramadol
,25211185,maximum concentration (Cmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),[μg] / [ml],0.08,228973,DB00193,Tramadol
,25211185,time to achieve maximum concentration (Tmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),h,0.75,228974,DB00193,Tramadol
,25211185,time to achieve maximum concentration (Tmax),"For M1 and M2, median maximum concentration (Cmax) and time to achieve maximum concentration (Tmax) were 0.05 μg/mL and 0.75 h, and 0.08 μg/mL and 2 h, respectively; M5 was never detected.",Clinical pharmacokinetics of tramadol and main metabolites in horses undergoing orchiectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25211185/),h,2,228975,DB00193,Tramadol
,28052590,flow rate,The microdialysis samples were separated on a C18 column and eluted with a mobile phase of acetonitrile-water-formic acid (50:50:0.1; v/v/v) at a flow rate of 0.3 mL/min.,Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),[ml] / [min],0.3,234079,DB00193,Tramadol
,28052590,m/z,"The ESI-MS/MS spectra were performed in electrospray positive ion mode, and the analytes were detected by multiple reaction monitoring (MRM) of the transitions m/z [M + H]+ 264.3 → 58.2 for tramadol, m/z [M + H]+ 250.3 → 58.3 for ODT, and m/z [M + H]+ 379.4 → 264.0 for ambroxol (internal standard; IS).",Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),,250.3,234080,DB00193,Tramadol
,28052590,m/z,"The ESI-MS/MS spectra were performed in electrospray positive ion mode, and the analytes were detected by multiple reaction monitoring (MRM) of the transitions m/z [M + H]+ 264.3 → 58.2 for tramadol, m/z [M + H]+ 250.3 → 58.3 for ODT, and m/z [M + H]+ 379.4 → 264.0 for ambroxol (internal standard; IS).",Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),,58.3,234081,DB00193,Tramadol
,28052590,m/z,"The ESI-MS/MS spectra were performed in electrospray positive ion mode, and the analytes were detected by multiple reaction monitoring (MRM) of the transitions m/z [M + H]+ 264.3 → 58.2 for tramadol, m/z [M + H]+ 250.3 → 58.3 for ODT, and m/z [M + H]+ 379.4 → 264.0 for ambroxol (internal standard; IS).",Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),,379.4,234082,DB00193,Tramadol
,28052590,m/z,"The ESI-MS/MS spectra were performed in electrospray positive ion mode, and the analytes were detected by multiple reaction monitoring (MRM) of the transitions m/z [M + H]+ 264.3 → 58.2 for tramadol, m/z [M + H]+ 250.3 → 58.3 for ODT, and m/z [M + H]+ 379.4 → 264.0 for ambroxol (internal standard; IS).",Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),,264.0,234083,DB00193,Tramadol
,28052590,total run time,The total run time was 4.0 min.,Intracerebral microdialysis coupled to LC-MS/MS for the determination tramadol and its major pharmacologically active metabolite O-desmethyltramadol in rat brain microdialysates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28052590/),min,4.0,234084,DB00193,Tramadol
,33657107,half-life,"When 4 mg/kg tramadol was administered, the median half-life of tramadol and M1 were 2.89 h and 24.69 h, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),h,2.89,240223,DB00193,Tramadol
,33657107,half-life,"When 4 mg/kg tramadol was administered, the median half-life of tramadol and M1 were 2.89 h and 24.69 h, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),h,24.69,240224,DB00193,Tramadol
,33657107,area under the curve M1: tramadol ratios,"When tramadol was administered at 2 mg/kg and 4 mg/kg the area under the curve M1: tramadol ratios were 0.33 and 0.50, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),,0.33,240225,DB00193,Tramadol
,33657107,area under the curve M1: tramadol ratios,"When tramadol was administered at 2 mg/kg and 4 mg/kg the area under the curve M1: tramadol ratios were 0.33 and 0.50, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),,0.50,240226,DB00193,Tramadol
,33657107,binding,"Tramadol and M1 binding to plasma protein were determined using thawed, frozen koala plasma and the mean binding was 20% and 75%, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),%,20,240227,DB00193,Tramadol
,33657107,binding,"Tramadol and M1 binding to plasma protein were determined using thawed, frozen koala plasma and the mean binding was 20% and 75%, respectively.",Pharmacokinetic profile of injectable tramadol in the koala (Phascolarctos cinereus) and prediction of its analgesic efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33657107/),%,75,240228,DB00193,Tramadol
,17192836,clearance,"Both enantiomers showed clearance values (62.5 +/- 27.2 and 64.4 +/- 39.0 ml/min/kg for (+)- and (-)-T, respectively) that were equal or higher than the reported liver blood flow in rats.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),[ml] / [kg·min],62.5,240684,DB00193,Tramadol
,17192836,clearance,"Both enantiomers showed clearance values (62.5 +/- 27.2 and 64.4 +/- 39.0 ml/min/kg for (+)- and (-)-T, respectively) that were equal or higher than the reported liver blood flow in rats.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),[ml] / [kg·min],64.4,240685,DB00193,Tramadol
,17192836,systemic availability,"However, the systemic availability of (+)-T was significantly (P < 0.05) higher than that of its antipode following intraperitoneal (0.527 +/- 0.240 vs. 0.373 +/- 0.189) and oral (0.307 +/- 0.136 vs. 0.159 +/- 0.115) administrations.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),,0.527,240686,DB00193,Tramadol
,17192836,systemic availability,"However, the systemic availability of (+)-T was significantly (P < 0.05) higher than that of its antipode following intraperitoneal (0.527 +/- 0.240 vs. 0.373 +/- 0.189) and oral (0.307 +/- 0.136 vs. 0.159 +/- 0.115) administrations.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),,0.373,240687,DB00193,Tramadol
,17192836,systemic availability,"However, the systemic availability of (+)-T was significantly (P < 0.05) higher than that of its antipode following intraperitoneal (0.527 +/- 0.240 vs. 0.373 +/- 0.189) and oral (0.307 +/- 0.136 vs. 0.159 +/- 0.115) administrations.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),,0.307,240688,DB00193,Tramadol
,17192836,systemic availability,"However, the systemic availability of (+)-T was significantly (P < 0.05) higher than that of its antipode following intraperitoneal (0.527 +/- 0.240 vs. 0.373 +/- 0.189) and oral (0.307 +/- 0.136 vs. 0.159 +/- 0.115) administrations.",Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192836/),,0.159,240689,DB00193,Tramadol
,15305853,half-life,"The calculated parameters for half-life, volume of distribution, and total body clearance were 0.80 +/- 0.12 h, 3.79 +/- 0.93 L/kg, and 54.63 +/- 8.19 mL/kg/min following 4.4 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),h,0.80,240959,DB00193,Tramadol
,15305853,volume of distribution,"The calculated parameters for half-life, volume of distribution, and total body clearance were 0.80 +/- 0.12 h, 3.79 +/- 0.93 L/kg, and 54.63 +/- 8.19 mL/kg/min following 4.4 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),[l] / [kg],3.79,240960,DB00193,Tramadol
,15305853,total body clearance,"The calculated parameters for half-life, volume of distribution, and total body clearance were 0.80 +/- 0.12 h, 3.79 +/- 0.93 L/kg, and 54.63 +/- 8.19 mL/kg/min following 4.4 mg/kg tramadol HCl administered intravenously.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),[ml] / [kg·min],54.63,240961,DB00193,Tramadol
,15305853,systemic availability,The systemic availability was 65 +/- 38% and half-life 1.71 +/- 0.12 h following tramadol 11 mg/kg p.o. M1 had a half-life of 1.69 +/- 0.45 and 2.18 +/- 0.55 h following intravenous and oral administration of tramadol.,Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),%,65,240962,DB00193,Tramadol
,15305853,half-life,The systemic availability was 65 +/- 38% and half-life 1.71 +/- 0.12 h following tramadol 11 mg/kg p.o. M1 had a half-life of 1.69 +/- 0.45 and 2.18 +/- 0.55 h following intravenous and oral administration of tramadol.,Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),h,1.71,240963,DB00193,Tramadol
,15305853,half-life,The systemic availability was 65 +/- 38% and half-life 1.71 +/- 0.12 h following tramadol 11 mg/kg p.o. M1 had a half-life of 1.69 +/- 0.45 and 2.18 +/- 0.55 h following intravenous and oral administration of tramadol.,Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),h,1.69,240964,DB00193,Tramadol
,15305853,half-life,The systemic availability was 65 +/- 38% and half-life 1.71 +/- 0.12 h following tramadol 11 mg/kg p.o. M1 had a half-life of 1.69 +/- 0.45 and 2.18 +/- 0.55 h following intravenous and oral administration of tramadol.,Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),h,2.18,240965,DB00193,Tramadol
,15305853,half-life,"Following intravenous M1 administration the half-life, volume of distribution, and clearance of M1 were 0.94 +/- 0.09 h, 2.80 +/- 0.15 L/kg, and 34.93 +/- 5.53 mL/kg/min respectively.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),h,0.94,240966,DB00193,Tramadol
,15305853,volume of distribution,"Following intravenous M1 administration the half-life, volume of distribution, and clearance of M1 were 0.94 +/- 0.09 h, 2.80 +/- 0.15 L/kg, and 34.93 +/- 5.53 mL/kg/min respectively.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),[l] / [kg],2.80,240967,DB00193,Tramadol
,15305853,clearance,"Following intravenous M1 administration the half-life, volume of distribution, and clearance of M1 were 0.94 +/- 0.09 h, 2.80 +/- 0.15 L/kg, and 34.93 +/- 5.53 mL/kg/min respectively.",Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15305853/),[ml] / [kg·min],34.93,240968,DB00193,Tramadol
,16713697,flow-rate,"Chromatographic separation was performed on a Hypurity C18 column (Thermo Hypersil-Keystone 2.1 mm x 150 mm, 5 microm, USA), The mobile phase was composed of 65% methanol and 35% water (contained 0.1% formic acid, 10 mM ammonium formate), which was run with a flow-rate of 0.2 ml/min at 40 degrees C.",Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ml] / [min],0.2,241323,DB00193,Tramadol
,16713697,limit of detection,The limit of detection for pseudoephedrine and cetirizine each was 5 ng/ml.,Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography-ion trap spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16713697/),[ng] / [ml],5,241324,DB00193,Tramadol
,10766364,overall recovery,The overall recovery of the analytes ranged from approximately 40 to 64% in rat plasma and 53-75% in dog plasma.,The determination of RWJ-38705 (tramadol N-oxide) and its metabolites in preclinical pharmacokinetic studies using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10766364/),%,40 to 64,252366,DB00193,Tramadol
,10766364,overall recovery,The overall recovery of the analytes ranged from approximately 40 to 64% in rat plasma and 53-75% in dog plasma.,The determination of RWJ-38705 (tramadol N-oxide) and its metabolites in preclinical pharmacokinetic studies using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10766364/),%,53-75,252367,DB00193,Tramadol
,20235455,terminal half-life,The terminal half-life of tramadol after intravenous dosing was 2.46 hours.,Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,2.46,256881,DB00193,Tramadol
,20235455,maximum plasma concentration,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),[ng] / [ml],2156.7,256882,DB00193,Tramadol
,20235455,time of maximum plasma concentration,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,3.75,256883,DB00193,Tramadol
,20235455,terminal half life,"The maximum plasma concentration, time of maximum plasma concentration, and terminal half life for tramadol after oral dosing were 2156.7 ng/ml, 3.75 hours, and 3.14 hours, respec vely.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),h,3.14,256884,DB00193,Tramadol
,20235455,oral bioavailability,"In addition, the oral bioavailability was 97.9%.",Pharmacokinetics of intravenous and oral tramadol in the bald eagle (Haliaeetus leucocephalus). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20235455/),%,97.9,256885,DB00193,Tramadol
,14624403,plasma area under the curve (AUC),"The total allelic frequencies of homozygote carriers were 0.015 and 0.25 for the CYP2D6*3 and *4 alleles, respectively, and the plasma area under the curve (AUC) was 84% above those of extensive metabolizers (homozygous EM group): 3,941.2 ng/mL.h (95% confidence interval [CI], 2,928.9 ng/mL.h to 4,953.5 ng/mL.h) versus 2,142.6 ng/mL.h (95% CI, 1,829.6 ng/mL.h to 2,455.7 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"3,941.2",259827,DB00193,Tramadol
,14624403,plasma area under the curve (AUC),"The total allelic frequencies of homozygote carriers were 0.015 and 0.25 for the CYP2D6*3 and *4 alleles, respectively, and the plasma area under the curve (AUC) was 84% above those of extensive metabolizers (homozygous EM group): 3,941.2 ng/mL.h (95% confidence interval [CI], 2,928.9 ng/mL.h to 4,953.5 ng/mL.h) versus 2,142.6 ng/mL.h (95% CI, 1,829.6 ng/mL.h to 2,455.7 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"2,928.9",259828,DB00193,Tramadol
,14624403,plasma area under the curve (AUC),"The total allelic frequencies of homozygote carriers were 0.015 and 0.25 for the CYP2D6*3 and *4 alleles, respectively, and the plasma area under the curve (AUC) was 84% above those of extensive metabolizers (homozygous EM group): 3,941.2 ng/mL.h (95% confidence interval [CI], 2,928.9 ng/mL.h to 4,953.5 ng/mL.h) versus 2,142.6 ng/mL.h (95% CI, 1,829.6 ng/mL.h to 2,455.7 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"4,953.5",259829,DB00193,Tramadol
,14624403,plasma area under the curve (AUC),"The total allelic frequencies of homozygote carriers were 0.015 and 0.25 for the CYP2D6*3 and *4 alleles, respectively, and the plasma area under the curve (AUC) was 84% above those of extensive metabolizers (homozygous EM group): 3,941.2 ng/mL.h (95% confidence interval [CI], 2,928.9 ng/mL.h to 4,953.5 ng/mL.h) versus 2,142.6 ng/mL.h (95% CI, 1,829.6 ng/mL.h to 2,455.7 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"2,142.6",259830,DB00193,Tramadol
,14624403,plasma area under the curve (AUC),"The total allelic frequencies of homozygote carriers were 0.015 and 0.25 for the CYP2D6*3 and *4 alleles, respectively, and the plasma area under the curve (AUC) was 84% above those of extensive metabolizers (homozygous EM group): 3,941.2 ng/mL.h (95% confidence interval [CI], 2,928.9 ng/mL.h to 4,953.5 ng/mL.h) versus 2,142.6 ng/mL.h (95% CI, 1,829.6 ng/mL.h to 2,455.7 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"2,455.7",259831,DB00193,Tramadol
,14624403,AUC,"Likewise, the AUC for the O-desmethyl-tramadol metabolite (M1) was significantly reduced in poor metabolizers (PMs): 300.2 ng/mL.h (95% CI, 260.3 ng/mL.h to 340.0 ng/mL.h) versus 842,6 ng/mL.h (95% CI, 715.1 ng/mL.h to 970.0 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],300.2,259832,DB00193,Tramadol
,14624403,AUC,"Likewise, the AUC for the O-desmethyl-tramadol metabolite (M1) was significantly reduced in poor metabolizers (PMs): 300.2 ng/mL.h (95% CI, 260.3 ng/mL.h to 340.0 ng/mL.h) versus 842,6 ng/mL.h (95% CI, 715.1 ng/mL.h to 970.0 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],340.0,259833,DB00193,Tramadol
,14624403,AUC,"Likewise, the AUC for the O-desmethyl-tramadol metabolite (M1) was significantly reduced in poor metabolizers (PMs): 300.2 ng/mL.h (95% CI, 260.3 ng/mL.h to 340.0 ng/mL.h) versus 842,6 ng/mL.h (95% CI, 715.1 ng/mL.h to 970.0 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],"842,6",259834,DB00193,Tramadol
,14624403,AUC,"Likewise, the AUC for the O-desmethyl-tramadol metabolite (M1) was significantly reduced in poor metabolizers (PMs): 300.2 ng/mL.h (95% CI, 260.3 ng/mL.h to 340.0 ng/mL.h) versus 842,6 ng/mL.h (95% CI, 715.1 ng/mL.h to 970.0 ng/mL.h).",A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14624403/),[ng] / [h·ml],970.0,259835,DB00193,Tramadol
,12016023,recovery,The method developed was selective and linear for concentrations ranging from 10 to 2000 ng/ml with average recovery of 98.63%.,Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016023/),%,98.63,261040,DB00193,Tramadol
,12016023,percentage recovery,The limit of quantitation (LOQ) was 10 ng/ml and the percentage recovery of the internal standard phenacetin was 76.51%.,Method development and validation of a high-performance liquid chromatographic method for tramadol in human plasma using liquid-liquid extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016023/),%,76.51,261041,DB00193,Tramadol
,23724656,flow rate,A microdialysis probe was implanted into the FrCx and perfused with artificial cerebrospinal fluid at a flow rate of 2 microL x min(-1).,[Pharmacokinetics of tramadol hydrochloride in the extracellular fluid of mouse frontal cortex studied by in vivo microdialysis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724656/),[μl] / [min],2,262502,DB00193,Tramadol
,23724656,t1/2alpha,"The results showed that the pharmacokinetic process of tramadol in the FrCx extracellular fluid of mice was fitted to a two-compartment open model, and the main pharmacokinetic parameters t1/2alpha, t1/2beta, t(max), C(max) and AUC(0-infinity) were (0.27 +/- 0.05) h, (2.72 +/- 0.24) h, (0.50 +/- 0.10) h, (2 110.37 +/- 291.22) microg x L(-1) and (4 474.51 +/- 441.79) microg x L(-1) x h, respectively.",[Pharmacokinetics of tramadol hydrochloride in the extracellular fluid of mouse frontal cortex studied by in vivo microdialysis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724656/),h,0.27,262503,DB00193,Tramadol
,23724656,AUC(0-infinity),"The results showed that the pharmacokinetic process of tramadol in the FrCx extracellular fluid of mice was fitted to a two-compartment open model, and the main pharmacokinetic parameters t1/2alpha, t1/2beta, t(max), C(max) and AUC(0-infinity) were (0.27 +/- 0.05) h, (2.72 +/- 0.24) h, (0.50 +/- 0.10) h, (2 110.37 +/- 291.22) microg x L(-1) and (4 474.51 +/- 441.79) microg x L(-1) x h, respectively.",[Pharmacokinetics of tramadol hydrochloride in the extracellular fluid of mouse frontal cortex studied by in vivo microdialysis]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724656/),[h·μg] / [l],4 474.51,262504,DB00193,Tramadol
,23724656,distribution-,"Tramadol hydrochloride shows a two-compartment model in the extracellular fluid of the mouse FrCx, and the distribution- and elimination half-life are 0.5 h and 2.7 h, respectively.",[Pharmacokinetics of tramadol hydrochloride in the extracellular fluid of mouse frontal cortex studied by in vivo microdialysis]. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724656/),h,0.5,262505,DB00193,Tramadol
,23724656,elimination half-life,"Tramadol hydrochloride shows a two-compartment model in the extracellular fluid of the mouse FrCx, and the distribution- and elimination half-life are 0.5 h and 2.7 h, respectively.",[Pharmacokinetics of tramadol hydrochloride in the extracellular fluid of mouse frontal cortex studied by in vivo microdialysis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724656/),h,2.7,262506,DB00193,Tramadol
,26352950,maximum plasma concentration,The results indicate that the plasma levels of parent tramadol are low or negligible during the first 30-45 min and then reach the predicted mean maximum plasma concentration of 358 ng/ml at 1.52 hr.,"PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE AND ITS METABOLITE O-DESMETHYLTRAMADOL FOLLOWING A SINGLE, ORALLY ADMINISTERED DOSE IN CALIFORNIA SEA LIONS (ZALOPHUS CALIFORNIANUS). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26352950/),[ng] / [ml],358,262760,DB00193,Tramadol
,19845931,elimination half-life,"Following cumulative IV administration of 3.1 mg kg(-1) and bolus IV administration of 2 mg kg(-1), the elimination half-life of tramadol was 1.91 +/- 0.33 and 2.1 +/- 0.9 hours, respectively.","Intravenous tramadol: effects, nociceptive properties, and pharmacokinetics in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845931/),h,1.91,263077,DB00193,Tramadol
,19845931,elimination half-life,"Following cumulative IV administration of 3.1 mg kg(-1) and bolus IV administration of 2 mg kg(-1), the elimination half-life of tramadol was 1.91 +/- 0.33 and 2.1 +/- 0.9 hours, respectively.","Intravenous tramadol: effects, nociceptive properties, and pharmacokinetics in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845931/),h,2.1,263078,DB00193,Tramadol
,19845931,HWRL,"Baseline HWRL and STRL were 4.16 +/- 1.0 and 3.06 +/- 0.99 seconds, respectively, and were not significantly prolonged by tramadol.","Intravenous tramadol: effects, nociceptive properties, and pharmacokinetics in horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845931/),seconds,4.16,263079,DB00193,Tramadol
,19845931,STRL,"Baseline HWRL and STRL were 4.16 +/- 1.0 and 3.06 +/- 0.99 seconds, respectively, and were not significantly prolonged by tramadol.","Intravenous tramadol: effects, nociceptive properties, and pharmacokinetics in horses. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19845931/),seconds,3.06,263080,DB00193,Tramadol
,23145962,Maximal measured plasma tramadol concentrations,"Maximal measured plasma tramadol concentrations were 454 ± 101.6, 1086.7 ± 330.7 and 1697.9 ± 406.1 ng/ml for 0.5, 1.5 and 3 mg/kg bwt, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],454,263187,DB00193,Tramadol
,23145962,Maximal measured plasma tramadol concentrations,"Maximal measured plasma tramadol concentrations were 454 ± 101.6, 1086.7 ± 330.7 and 1697.9 ± 406.1 ng/ml for 0.5, 1.5 and 3 mg/kg bwt, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],1086.7,263188,DB00193,Tramadol
,23145962,Maximal measured plasma tramadol concentrations,"Maximal measured plasma tramadol concentrations were 454 ± 101.6, 1086.7 ± 330.7 and 1697.9 ± 406.1 ng/ml for 0.5, 1.5 and 3 mg/kg bwt, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],1697.9,263189,DB00193,Tramadol
,23145962,clearance,"Depending on the dose administered, the tramadol clearance, volume of distribution and half-life ranged from 24.6 to 25.0 ml/min/kg, 2.66 to 3.33 l/kg and 2.17 to 3.05 h, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ml] / [kg·min],24.6 to 25.0,263190,DB00193,Tramadol
,23145962,volume of distribution,"Depending on the dose administered, the tramadol clearance, volume of distribution and half-life ranged from 24.6 to 25.0 ml/min/kg, 2.66 to 3.33 l/kg and 2.17 to 3.05 h, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[l] / [kg],2.66 to 3.33,263191,DB00193,Tramadol
,23145962,half-life,"Depending on the dose administered, the tramadol clearance, volume of distribution and half-life ranged from 24.6 to 25.0 ml/min/kg, 2.66 to 3.33 l/kg and 2.17 to 3.05 h, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),h,2.17 to 3.05,263192,DB00193,Tramadol
,23145962,maximal measured plasma concentrations,"Following administration of 0.5, 1.5 and 3 mg/kg bwt tramadol, the maximal measured plasma concentrations of the active metabolite, O-desmethyltramadol, were 3.9 ± 1.9, 9.6 ± 4.8 and 12.9 ± 5.2 ng/ml, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],3.9,263193,DB00193,Tramadol
,23145962,maximal measured plasma concentrations,"Following administration of 0.5, 1.5 and 3 mg/kg bwt tramadol, the maximal measured plasma concentrations of the active metabolite, O-desmethyltramadol, were 3.9 ± 1.9, 9.6 ± 4.8 and 12.9 ± 5.2 ng/ml, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],9.6,263194,DB00193,Tramadol
,23145962,maximal measured plasma concentrations,"Following administration of 0.5, 1.5 and 3 mg/kg bwt tramadol, the maximal measured plasma concentrations of the active metabolite, O-desmethyltramadol, were 3.9 ± 1.9, 9.6 ± 4.8 and 12.9 ± 5.2 ng/ml, respectively.",Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23145962/),[ng] / [ml],12.9,263195,DB00193,Tramadol
,19473603,Maximum exposure,Maximum exposure of tramadol (geometric means of C(max)-values) was determined as 289.3 ng/ml after morning and 283.1 ng/ml after evening administration.,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[ng] / [ml],289.3,267913,DB00193,Tramadol
,19473603,Maximum exposure,Maximum exposure of tramadol (geometric means of C(max)-values) was determined as 289.3 ng/ml after morning and 283.1 ng/ml after evening administration.,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[ng] / [ml],283.1,267914,DB00193,Tramadol
,19473603,C(max),Maximum exposure of tramadol (geometric means of C(max)-values) was determined as 289.3 ng/ml after morning and 283.1 ng/ml after evening administration.,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[ng] / [ml],289.3,267915,DB00193,Tramadol
,19473603,C(max),Maximum exposure of tramadol (geometric means of C(max)-values) was determined as 289.3 ng/ml after morning and 283.1 ng/ml after evening administration.,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[ng] / [ml],283.1,267916,DB00193,Tramadol
,19473603,AUC(0-48),"Extent of tramadol exposure (geometric means of AUC(0-48)-values) was calculated as 4,802.5 ng x h/ml after morning and 4,767.0 ng x h/ml after evening administration.",Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[h·ng] / [ml],"4,802.5",267917,DB00193,Tramadol
,19473603,AUC(0-48),"Extent of tramadol exposure (geometric means of AUC(0-48)-values) was calculated as 4,802.5 ng x h/ml after morning and 4,767.0 ng x h/ml after evening administration.",Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),[h·ng] / [ml],"4,767.0",267918,DB00193,Tramadol
,19473603,tmax,Also tmax-values were comparable after morning and evening administration (9.00 vs. 9.50 hours).,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),h,9.00,267919,DB00193,Tramadol
,19473603,tmax,Also tmax-values were comparable after morning and evening administration (9.00 vs. 9.50 hours).,Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19473603/),h,9.50,267920,DB00193,Tramadol
,20456744,metabolic ratio,"The 32-h metabolic ratio of tramadol to M(1) were (mean +/- SD) 2.05 +/- 1.01, 2.13 +/- 0.83, 4.24 +/- 2.75 and 6.85 +/- 2.78, respectively, in CYP2D6*1/*1, CYP2D6*2/*2, CYP2D6*2/*10 and CYP2D6*10/*10 subjects, respectively.",Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456744/),,2.05,268883,DB00193,Tramadol
,20456744,metabolic ratio,"The 32-h metabolic ratio of tramadol to M(1) were (mean +/- SD) 2.05 +/- 1.01, 2.13 +/- 0.83, 4.24 +/- 2.75 and 6.85 +/- 2.78, respectively, in CYP2D6*1/*1, CYP2D6*2/*2, CYP2D6*2/*10 and CYP2D6*10/*10 subjects, respectively.",Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456744/),,2.13,268884,DB00193,Tramadol
,20456744,metabolic ratio,"The 32-h metabolic ratio of tramadol to M(1) were (mean +/- SD) 2.05 +/- 1.01, 2.13 +/- 0.83, 4.24 +/- 2.75 and 6.85 +/- 2.78, respectively, in CYP2D6*1/*1, CYP2D6*2/*2, CYP2D6*2/*10 and CYP2D6*10/*10 subjects, respectively.",Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456744/),,4.24,268885,DB00193,Tramadol
,20456744,metabolic ratio,"The 32-h metabolic ratio of tramadol to M(1) were (mean +/- SD) 2.05 +/- 1.01, 2.13 +/- 0.83, 4.24 +/- 2.75 and 6.85 +/- 2.78, respectively, in CYP2D6*1/*1, CYP2D6*2/*2, CYP2D6*2/*10 and CYP2D6*10/*10 subjects, respectively.",Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20456744/),,6.85,268886,DB00193,Tramadol
,17361124,area under the concentration-time curves,"Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng x h/ml for PMs, HZ/IMs, EMs, and UMs (P<0.001).",Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361124/),[h·ng] / [ml],0,269299,DB00193,Tramadol
,17361124,area under the concentration-time curves,"Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng x h/ml for PMs, HZ/IMs, EMs, and UMs (P<0.001).",Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361124/),[h·ng] / [ml],11.4,269300,DB00193,Tramadol
,17361124,area under the concentration-time curves,"Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng x h/ml for PMs, HZ/IMs, EMs, and UMs (P<0.001).",Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361124/),[h·ng] / [ml],38.6,269301,DB00193,Tramadol
,17361124,area under the concentration-time curves,"Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng x h/ml for PMs, HZ/IMs, EMs, and UMs (P<0.001).",Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361124/),[h·ng] / [ml],66.5,269302,DB00193,Tramadol
,17361124,area under the concentration-time curves,"Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng x h/ml for PMs, HZ/IMs, EMs, and UMs (P<0.001).",Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17361124/),[h·ng] / [ml],149.7,269303,DB00193,Tramadol
,21370741,bioavailability,"The bioavailability of the drug, ranging between 84-102% (mean 92%), was within the generally accepted values for a positive bioequivalence decision of (80-125%).",Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21370741/),%,84-102,270001,DB00193,Tramadol
,21370741,bioavailability,"The bioavailability of the drug, ranging between 84-102% (mean 92%), was within the generally accepted values for a positive bioequivalence decision of (80-125%).",Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21370741/),%,92,270002,DB00193,Tramadol
,21370741,T(max),After the i.m. injection the mean plasma drug concentration peak was reached after a T(max) of 0.34 h with a C(max) of 2.52 microg/mL.,Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21370741/),h,0.34,270003,DB00193,Tramadol
,21370741,C(max),After the i.m. injection the mean plasma drug concentration peak was reached after a T(max) of 0.34 h with a C(max) of 2.52 microg/mL.,Pharmacokinetics of tramadol and metabolites after injective administrations in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21370741/),[μg] / [ml],2.52,270004,DB00193,Tramadol
,32424860,IC50,"The IC50 of shikonin on tramadol metabolism was 5.66 ± 1.2 μmol/l in HLM and 3.35 ± 1.1 μmol/l in RLM, while that of DSK on tramadol metabolism was 14.33 ± 1.1 μmol/l in HLM and 8.24 ± 1.26 μmol/l in RLM.","The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32424860/),[μM] / [l],5.66,270820,DB00193,Tramadol
,32424860,IC50,"The IC50 of shikonin on tramadol metabolism was 5.66 ± 1.2 μmol/l in HLM and 3.35 ± 1.1 μmol/l in RLM, while that of DSK on tramadol metabolism was 14.33 ± 1.1 μmol/l in HLM and 8.24 ± 1.26 μmol/l in RLM.","The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32424860/),[μM] / [l],3.35,270821,DB00193,Tramadol
,32424860,IC50,"The IC50 of shikonin on tramadol metabolism was 5.66 ± 1.2 μmol/l in HLM and 3.35 ± 1.1 μmol/l in RLM, while that of DSK on tramadol metabolism was 14.33 ± 1.1 μmol/l in HLM and 8.24 ± 1.26 μmol/l in RLM.","The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32424860/),[μM] / [l],14.33,270822,DB00193,Tramadol
,32424860,IC50,"The IC50 of shikonin on tramadol metabolism was 5.66 ± 1.2 μmol/l in HLM and 3.35 ± 1.1 μmol/l in RLM, while that of DSK on tramadol metabolism was 14.33 ± 1.1 μmol/l in HLM and 8.24 ± 1.26 μmol/l in RLM.","The inhibitory effects of shikonin and β,β-dimethylacrylshikonin on tramadol metabolism in vitro and in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32424860/),[μM] / [l],8.24,270823,DB00193,Tramadol
,21988424,steady-state transdermal absorption rate,"In the in-vivo pharmacokinetic study, plasma concentrations of tramadol steadily increased and reached steady state (336 ng/ml) 3 h after initiation of current supply, and the in-vivo steady-state transdermal absorption rate was 499 µg/cm(2) per h as calculated by a constrained numeric deconvolution method.","In-vitro and in-vivo transdermal iontophoretic delivery of tramadol, a centrally acting analgesic. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988424/),[μg] / [cm(2)·h],499,272266,DB00193,Tramadol
,18177320,clearance,"Tramadol clearance, apparent volume of distribution at steady-state, mean residence time (MRT) and half-life after intravenous administration were 26+/-3 mL/min/kg, 2.17+/-0.52 L/kg, 83+/-10 min, and 82+/-10 min, respectively.","Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),[ml] / [kg·min],26,272632,DB00193,Tramadol
,18177320,apparent volume of distribution at steady-state,"Tramadol clearance, apparent volume of distribution at steady-state, mean residence time (MRT) and half-life after intravenous administration were 26+/-3 mL/min/kg, 2.17+/-0.52 L/kg, 83+/-10 min, and 82+/-10 min, respectively.","Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),[l] / [kg],2.17,272633,DB00193,Tramadol
,18177320,mean residence time (MRT),"Tramadol clearance, apparent volume of distribution at steady-state, mean residence time (MRT) and half-life after intravenous administration were 26+/-3 mL/min/kg, 2.17+/-0.52 L/kg, 83+/-10 min, and 82+/-10 min, respectively.","Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),[l] / [kg],2.17,272634,DB00193,Tramadol
,18177320,mean residence time (MRT),"Tramadol clearance, apparent volume of distribution at steady-state, mean residence time (MRT) and half-life after intravenous administration were 26+/-3 mL/min/kg, 2.17+/-0.52 L/kg, 83+/-10 min, and 82+/-10 min, respectively.","Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),min,83,272635,DB00193,Tramadol
,18177320,half-life,"Tramadol clearance, apparent volume of distribution at steady-state, mean residence time (MRT) and half-life after intravenous administration were 26+/-3 mL/min/kg, 2.17+/-0.52 L/kg, 83+/-10 min, and 82+/-10 min, respectively.","Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),min,82,272636,DB00193,Tramadol
,18177320,MRT,The MRT and half-life after intramuscular administration were 155+/-23 and 92+/-14 min.,"Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),min,155,272637,DB00193,Tramadol
,18177320,half-life,The MRT and half-life after intramuscular administration were 155+/-23 and 92+/-14 min.,"Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),min,92,272638,DB00193,Tramadol
,18177320,mean absorption time,The mean absorption time was 72+/-22 min and the bioavailability 111+/-39%.,"Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),min,72,272639,DB00193,Tramadol
,18177320,bioavailability,The mean absorption time was 72+/-22 min and the bioavailability 111+/-39%.,"Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18177320/),%,111,272640,DB00193,Tramadol
,11730570,relative recoveries,"For the enantiomers of trans-T and M1, the intra-day and inter-day RSD were less than 15 % and 20 %, and the relative recoveries were 94.3 %-106.2 % and 90.4 %-107.8 %, respectively; the limit of quantitation was 1.25 microg/L.","Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730570/),%,94.3,273303,DB00193,Tramadol
,11730570,relative recoveries,"For the enantiomers of trans-T and M1, the intra-day and inter-day RSD were less than 15 % and 20 %, and the relative recoveries were 94.3 %-106.2 % and 90.4 %-107.8 %, respectively; the limit of quantitation was 1.25 microg/L.","Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730570/),%,106.2,273304,DB00193,Tramadol
,11730570,relative recoveries,"For the enantiomers of trans-T and M1, the intra-day and inter-day RSD were less than 15 % and 20 %, and the relative recoveries were 94.3 %-106.2 % and 90.4 %-107.8 %, respectively; the limit of quantitation was 1.25 microg/L.","Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730570/),%,90.4,273305,DB00193,Tramadol
,11730570,relative recoveries,"For the enantiomers of trans-T and M1, the intra-day and inter-day RSD were less than 15 % and 20 %, and the relative recoveries were 94.3 %-106.2 % and 90.4 %-107.8 %, respectively; the limit of quantitation was 1.25 microg/L.","Pharmacokinetics of enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in human subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11730570/),%,107,273306,DB00193,Tramadol
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],22.4,273696,DB00193,Tramadol
,9706948,Cmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),[mg] / [l],26.8,273697,DB00193,Tramadol
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,33,273698,DB00193,Tramadol
,9706948,Tmax,"Tramadol had measurable but statistically insignificant inhibitory effects on gastric emptying compared with saline (mean +/- SEM: Cmax 22.4 +/- 2.2 vs 26.8 +/- 2.5 mg/L [P = 0.19], Tmax 33 +/- 5.4 vs 19.5 +/- 2.3 min [P = 0.054] for tramadol versus saline, respectively).","A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),min,19.5,273699,DB00193,Tramadol
,9706948,Tmax,The Tmax value for codeine (63.3 +/- 11.7) was greater than that for tramadol (P = 0.034).,"A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9706948/),,63.3,273700,DB00193,Tramadol
